Author Index to Volume 115

A

Abbott, R. L., 2125
Abramoff, M. D., 1591
Abramson, D. H., 1398
Adams, S., 1209
Adan, E. S., 2004
Adewoyin, T., 2192
Advanced Imaging for Glaucoma Study Group, 949, 1352
Aerts, I., 1405
Agarwal, A., 520
Agrón, E., 181
Ahmadieh, H., 1938
Aiello, L. P., 1366
Ainbinder, D. J., 377
Aisenbrey, S., 1750
Akpek, E. K., 614
Aldahmesh, M. A., 730
AlDrees, A., 2286
Alencar, L. M., 934, 1340
Alexander, J., 1468
Alexander, M. Y., 1550
Alfonso, E. C., 1303, 1501, 1517
Alfred, T., 1720
Allan, B. D., 455
Allingham, R. R., 763
Almony, A., 540
Alorainy, I. A., 2286
Alsbirk, P. H., 700, 1286, 2024
Al-Sharif, L., 2262
Al-Tassan, N., 2262
Amano, S., 911
Amar, N., 1154
American Academy of Ophthalmology Medical Information Technology Committee, 1591
Andersen, M. V. N., 700
Anderson, D. R., 661, 957
Anderson, S., 904
Andrew, T., 1545
Ang, A., 164
Ang, L. P. K., 975
Anhalt, G. J., 2146
Annunziata, C. C., 744
Antoszyk, A. N., 1876
Apple, D. J., 73
Applegate, C. A., 1480
Araie, M., 363, 1585, 2049
Araujo, D. M., 483
AREDS Research Group, 1026
Arita, R., 911
Armitage, W. J., 268
Armstrong, J., 1026
Arrowsmith, P. N., 464
Arvind, H., 648, 655
Arzeno, G., 1728
Asadi, R., 67
Asaria, R., 1930
Aslam, S. A., 1705
Asselain, B., 1405
Assil, K. K., 464
Atebara, N. H., 540
Auclair, P. L., 2065
Aung, H. T., 769, 1720
Aung, T., 26, 430, 769, 964, 1713, 1720, 1735, 1869, 1973
Austin, M., 2058
Ayyagari, P., 1315
Azen, S., 1422
Azen, S. P., 227, 319, 639, 815, 941

B

Baasanhu, J., 2024
Babu, J. G., 1167
Babu, R. B., 287
Bahar, I., 1525
Balu, R., 287
Barañano, A. E., 815
Barbados Eye Studies Group, 2153
Barnes, S. D., 377
Bar-Sela, S. M., 104
Bartov, E., 686
Baskaran, M., 430, 648, 655
Baudouin, C., 109, 1154
Behrens, M. M., 904
Beigi, B., 1608
Beiser, J. A., 1550
Belkin, M., 686
Bell, W. R., 893
Belsky, D., 1109
Benavides, R., 511
Bengtsson, B., 1557, 2044
Berdahl, J. P., 763
Bergamini, M. V. W., 1728
Berman, E. L., 546
Bernardino, C. R., 2065
Bernstein, P. S., 147
Berrocal, A. M., 473
BESs Study Group, 85
Bessho, K., 1771
Bilonick, R. A., 673
Bird, A. C., 342, 700
Blaydon, S. M., 377
Bloom, P. A., 993, 2058
Boekhoorn, S. S., 608, 1899
Bojanowski, C. M., 1891
Boland, M. V., 1591
Booton, G. C., 1998
Bor, Z., 1187
Borchert, M., 1245, 1422
Borch-Johnsen, K., 700
Bosley, T. M., 2262
Bostrom, A. G., 440
Bours, D., 1405
Bowd, C., 934
Bower, K. S., 2087, 2235
Boxer Wachler, B. S., 1249
Boyer, K., 553
Boyle, M., 1241
Bradley, D. J., 398
Bradley, E. A., 398
Brandt, J. D., 1550
Braun, E. H. P., 1196
Bremner, A. P., 3
Bressler, N. M., 1032, 1366, 1480
Bressler, S. B., 1026, 1032, 1366
Breteler, M. M. B., 887
Brian, G., 1655
Brignole-Baudouin, F., 109
Brinzolamide 1%/Timolol 0.5% Study Group, 1728
British Congenital Cataract Interest Group, 1013
Brodie, S. E., 1398
Broman, A., 1480
Broman, A. T., 202
Brown, G. C., 1039, 1837
Brown, H. C., 1039
Brown, M. M., 1039, 1837
Brown, S. A., 1053
Browning, D. J., 533, 1366
Brubaker, J. W., 347
Budenz, D. L., 661
Buggage, R., 116
Bulsara, M. K., 3
Bunce, C., 253, 342
Burgansky-Eliash, Z., 673
Buring, J. E., 822
Burke, G. L., 1742
Burke, J. P., 169
Burkom, D., 1786
Burla, N., 104
Burlutsky, G., 693, 1273, 1693
Butman, J. A., 1382
Butt, A. L., 1297
Buys, Y. M., 1130

C

Cahill, K. V., 398
Caldwell, J., 520
Campbell, I., 1778
Cantor, L. B., 1141
Capone Jr, A., 1065, 1209
Caprioli, J., 1123
Capris, E., 1358
Carbonaro, F., 1545
CAREDS Macular Pigment Study Group, 876
CARMIS Study Group, 324
Carroll, R. B., 377
Carstensen, B., 700
Cartmill, B., 1046
Cashwell, L. F., 927
Casson, R. J., 26
Casuccio, A., 1508
CAT-152 Trabeculectomy Study Group, 1103
Cavuoto, K., 51
Cej, A., 1372
Centofanti, M., 1358

Cezar, S., 553
Chak, M., 1013
Chakravarthy, U., 116, 1046
Challa, P., 738
Chan, C.-C., 693, 1891
Chan, C. H. Y., 2167
Chan, J. C. H., 2167
Chan, K. C. Y., 667
Chan, L.-L., 503
Chan, W., 1046
Chan, W.-M., 1756
Chan, Y.-H., 975, 1713
Chandra, S. R., 1026
Chang, E. L., 1613
Chang, K. T., 2206
Chang, S. H. L., 1173
Chappell, R., 876
Charkoudian, L. D., 1032
Chauhan, B. C., 1557
Chen, C. Y., 1053
Chen, D., 80
Chen, E. S., 488, 497, 1179
Chen, S.-N., 2229
Chen, X., 830
Cheng, C. Y., 1742
Cheng, C.-Y., 1334
Cheng, S.-T., 1173
Cheung, C. Y. L., 796, 1347
Cheung, N., 1869, 1951
Chew, E. Y., 181, 822, 1026, 1382, 1891, 1957
Chew, P. T. K., 430
Chi, C. C., 2167
Chia, E.-M., 808
Chiang, M. F., 1222, 1591
Chiang, T. H., 11, 633
Chiang, Y.-H., 734
Chien, C.-T., 734
Chihara, H., 292
Chikaraishi, Y., 1916
Chipman, M. L., 1130
Chiu, R., 80
Chiu, T. Y. H., 1134, 2167
Chodosh, J., 1297
Choi, S. S., 1923
Chong, E. W., 597, 1973
Chong, N. V., 2192
Chopra, V., 227
Christen, W., 1416
Christen, W. G., 822
Chui, W., 80
Chun, D. W., 2087
Cillino, G., 1508
Cillino, S., 1508
Clark, S., 533
Clinical Trial of Nutritional Supplements and Age-Related Cataract Study Group, 599
Cochran, D. E., 319
Cohen, S. R., 744
Coki, O., 1222
Coleman, A. L., 18, 1123
Coleman, H. R., 181, 1957
Collaborative Initial Glaucoma Treatment Study Group, 927
Collaborative Ocular Melanoma Study Group, 1390
Collins, A. T., 347
Colyer, M. H., 2087, 2235
Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group, 1468, 1474, 1876
Cook, S. D., 268
Coppé, A. M., 1489
Cornea Donor Study Investigator Group, 620, 627
Cotch, M. F., 1742
Cotran, P. R., 447
Cotter, S., 1422
Coupland, S. E., 1598, 1778
Craig, J. E., 1053
Creuzot-Garcher, C., 109
Cruysberg, J. R. M., 870
Csaky, K., 181
Culbertson, W. W., 1303, 1517
Cunliffe, I., 1557
Custer, P. L., 398

D

Dahr, S. S., 1382
Daimon, M., 1376
Damato, B., 1598, 1778
Dandekar, S. S., 342
Danesh-Meyer, H. V., 1566
Danforth, L. G., 1203
Daniels, J. T., 1989
Danis, R. P., 1366
Dart, J. K., 1989
Dart, J. K. G., 253, 1647, 1655
Davis, J. L., 473
Davis, M. D., 1366
Davitt, B. V., 1058
Dawson, D. G., 2181
de Boer, J. H., 306
de Groot-Mijnes, J. D. F., 306, 2062
de Jong, F. J., 887
de Jong, P. T. V. M., 887, 1899, 2037
De Kaspar, H. M., 2013
de Keizer, R. J. W., 195
de Sanctis, U., 1534
de Visser, L., 306
de Wolff-Rouendaal, D., 195
DeAngelis, M. M., 1209
Del Priore, L. V., 540
DeMartelaere, S. L., 377
Demer, J. L., 2079
Demirci, H., 383, 1626, 2295
Demirel, S., 2127
Dendale, R., 1405
Deneen, J., 1422
Deobhakta, A., 1517
Desjardins, L., 1405
Diabetic Retinopathy Clinical Research Network, 1366, 1447
Di Pace, F., 1508
Dick, J. S. B., 2087
Dickersin, K., 1809
Dickerson, J. E., 1728
Diehl, N. N., 169
Dinh, D. H., 546
Dobson, V., 1058
Dogru, M., 1982, 2004
Dohlman, C. H., S21
Dolgitser, M., 11, 633
Donaldson, K. E., 1517
Doshi, V., 639
Douglas, I., 1904
Doyle, J. J., 11, 633
Doyle, V., 1443
Doz, F., 1405
Drake, R. L., 560
Drenser, K. A., 884, 1065
Dryja, T. P., 1209
Du, L., 830
Duan, X. R., 1965
Dubbelman, M., 1679, 2017
Dubovy, S. R., 2181
Duker, J. S., 782
Dunkel, I. J., 1398
Dunn, J. P., 1826
Dupas, B., 1154
Dupps Jr, W. J., 560
Durrani, O. M., 386
Dustin, L., 319, 2206
Dzau, J. R., 1645

E

Eagle Jr, R. C., 511, 1673
Early Retreatment Study Group, 134
Early Treatment for Retinopathy of Prematurity Cooperative Group, 1058
Edelhauser, H. F., 2181
Edwards, K., 1655
Ee, A. G., 1720
Efremova, R., 99
Egbert, P. R., 2013
Eiseman, A. S., 2235
Eleuteri, A., 1598
Ellwein, L. B., 1645
Elmalik, S. A., 2286
El-Yaniv, R., 686
EMGT Group, 2044
Enzer, Y. R., 573
Erdem, U., 57
Ernst, E., 435
Esmaeli, B., 483
Espandar, L., 483
Esteve, M., 1405
Ezra, D. G., 435, 455

F

Fabian, E., 1308
Faghihi, A.-R., 425
Fahrbach, K., 116
Falkenstein, I. A., 319
Fan, D. S. P., 1134
Fan, X., 2290
Fang, W., 312
Fannin, L. A., 377
Farjo, A. A., 1249
Favaloro, E. J., 693
Feghhi, M., 1938
Feke, G. T., 246
Feldon, S. E., 1809
Feng, X., 1891

Ferreras, A., 775
Ferris III, F. L., 1026, 1366, 1891
Feuer, W., 51, 957, 1291, 1699
Feuer, W. J., 661
Ficker, L. A., 1705
Filippopoulos, T., 573
Fine, S. L., 1468
Fisher, A. C., 1598
Fishman, G. A., 723
Fletcher, A., 1904
Fletcher, A. E., 1046
Fletcher, E. C., 2192
Flood, V., 334
Flynn Jr, H. W., 473, 1501
Flynn, J. T., 1222
Fogagnolo, P., 1358
Fong, C. W., 802
Foong, A. W. P., 802
Foster, C. S., 1416
Foster, P. J., 769, 802, 964, 1286, 1720, 2024
Fotedar, R., 1273
Francis, B. A., 227, 1089
Francis, P. J., 1019
Fraser, C. M., 533
Fraunfelder, F. W., 2282
Frazer, D. G., 276
Fredette, M.-J., 661, 957
Freeman, E. E., 233
Freeman, W. R., 319
Friberg, T. R., 174
Frick, K. D., 11
Friedman, D. S., 233, 430, 769, 1320, 1720, 1786, 1796, 1965
Friend, D. J., 488, 497, 1179
Frueh, B. R., 2295
Fu, Y., 2290
Fuijkschot, J., 870
Fujii, H., 147
Fujikado, T., 1771
Fujimoto, H., 1494
Fujimoto, J. G., 782
Fujishima, H., 2004
Fukagawa, K., 1982, 2004
Fullen, D. R., 2295
Furuta, M., 546

G

Gabriele, M. L., 673, 782
Gaddipati, R. V., 1083
Galler, K. E., 1620
Gallinaro, G., 324
Gallins, P., 520
Galor, A., 1540, 1826
Gamble, G. D., 1566
Gangnon, R., 1859
Gangnon, R. E., 477, 1460
Gao, H., 769, 1720
Gardiner, S. K., 2127
Garnham, L., 1930
Garretson, B. R., 884
Gawley, S. D., 276
Gaytan, J., 1002
Gelb, L., 1320
Gelb, L. D., S35
George, R., 648, 655
George, R. K., 377
Gerl, R., 1308
Ghassemi, F., 2253
Gilchrist, S. E. C. M., 1046
Gilhotra, J., 1911
Gill, H., 1944
Gillespie, B. W., 927
Giordano, L., 1786, 1796
Glassman, A. R., 1366
Gloria, D. G., 279
Glynn, R. J., 822
Gobin, Y. P., 1398
Gohto, Y., 147
Goldberg, M. F., 893
Goldenfeld, M., 104
Goldman, D., 1303
Golnik, K. C., 1426
Gomi, F., 141, 1494, 1571, 1771
Good, W. V., 1058
Goodburn, S. F., 164
Gordon, M. O., 898, 1550
Goulet III, R. J., 1141
Gower, E. W., 398, 1032
Grant, M. P., 202
Grant-Jordan, P., 723
Graydon, R., 1046
Green, W. R., 614, 893
Greenberg, P. B., 573
Greenfield, D. S., 1352
Gregor, Z. J., 1930
Grentzelos, M. A., 2174
Grewal, D. S., 2141
Grewal, S. P. S., 2141
Grignolo, F. M., 1534
Gris, O., 1002
Grisanti, S., 1750
Grossniklaus, H. E., 2065, 2181
Grotto, I., 686
Grover, L. K., 904
Güell, J. L., 1002
Gunasekera, V., 435
Gupta, A., 26
Guymer, R. H., 1911

H

Ha, B. J., 1089
Habib, M. S., 525
Habot-Wilner, Z., 104
Hahn, S. R., 1320
Haines, J. L., 520
Håkansson, N., 1687
Hamard, P., 109, 1154
Hammel, K., 1957
Hammond, C. J., 1053, 1545
Hamon, S. C., 1019
Han, Y., 440
Handa, S., 430
Handan Eye Study Group, 1965
Hangai, M., 355, 1071
Hara, H., 1916
Hara, Y., 292
Hardy, R. J., 1058
Harman, F. E., 993
Harper, C. A., 1911
Harring, A. J., 1209
Hartstein, M., 744
Hartzell, K., 2246
Hasegawa, J., 988
Hasegawa, T., 2049
Hatef, E., 483
Hatt, S. R., 371
Hattori, T., 2215
Hauser, M. A., 520
Hawes, P., 1786
Hawkins, B. S., 1480
Hawse, P., 1796
Hayreh, S. S., 298, 1818, 2275
He, M., 1286
Heckenlively, J. R., 925
Heijl, A., 1557, 2044
Hendlish, S. K., 11
Heng, D., 802
Henke-Fahle, S., 1750
Hennis, A., 85, 2153
Hermans, E. A., 2017
Herz, N. L., 866
Hewitt, A. W., 1053
Hidayat, A. A., 1237
Hildebrand, P. L., 255, 1591
Hildreth, A. J., 525
Hill, S., 174
Hindman, H. B., 202
Hiramitsu, T., 147
Hirano, T., 147
Hiraoka, T., 1216
Hirst, L. W., 1663
Ho, A. C., 1837
Ho, W.-J., 1173
Hoar, K. L., 488, 497, 1179
Hoberman, D. M., 546
Hodapp, E. A., 1089
Hodge, D. O., 169, 790
Hofman, A., 887, 1899, 2037
Hogg, R. E., 1046
Holck, D. E., 398
Holden, B. A., 1655
Holekamp, N. M., 540
Holleschau, A. M., 1805
Hollyfield, J. G., 1540
Holmes, J. M., 371
Honkanen, R., 85
Honrubia, F. M., 775
Hood, D. C., 904
Hori-Komai, Y., 839
Hoskins Jr, H. D., 225, 2125
Hotta, Y., 147
Hoyer, H., 1308
Hsiao, Y.-C., 1328
Hsieh, J.-W., 1328
Hsu, W., 1951
Hsu, W.-M., 1334
Htoon, H. M., 975
Hu, J., 33
Hu, Y., 2004
Hua, S. Y., 1728
Huang, D., 949, 1249, 1352, 2159
Huang, J.-S., 734
Huang, S. S., 1366, 1837
Huang, W., 1286
Huchun, A., 377

Hunold, W., 1308
Hunter, D. G., 1800
Hütz, W., 1308
Huynh, S., 1279
Hwang, J.-F., 2229
Hwang, T. S., 1026
Hyman, L., 1557

I

Ibironke, J., 1786, 1796
Ide, T., 1303
Iester, M., 1358
Iida, T., 718
Ikeda, F., 718
Ikram, M. A., 887
Ikram, M. K., 887
Ikuno, Y., 141, 1571
Inatomi, T., 292
Inoue, K., 911
Inoue, Y., 988
Insull, E. A., 667
Ip, J., 1279
Ip, J. M., 678
Ip, M. S., 1837
Isaacs, A., 1899
Ischemic Optic Neuropathy Decompression Trial Research Group, 1809
Iseki, K., 147
Ishikawa, H., 673, 782
Islam, F. M. A., 1693
Israeli, E., 686
Itoh, K., 911
Iwase, A., 363
Izatt, J. A., 1883
Izuta, H., 1916

J

Jabs, D. A., 1826, 2146
Jackson, A. J., 276
Jacobs Jr, D. R., 1742
Jacobs, D. S., 2301
Jagadeesan, R., 738
Jain, R., 2141
Jalbrzikowski, J., 553
James, J. E., 1728
Jampel, H. D., 233, 239, 1089
Janardhanan, P., 975
Jansonius, N. M., 2037
Javitt, J. C., 1107
Jaycock, P. D., 268
Jeng, B. H., 1540
Jeoung, J. W., 2132
Ji, F., 1209
Ji, G., 1376
Jiang, L., 2079
Jirawuthiworavong, G. V., 1382
Joeres, S., 347
John, M. E., 464
Johnson, A. J., 377
Johnson, D. H., 763, 790
Johnson, G. J., 2024
Johnson, T. M., 2295
Jonas, J. B., 1372
Jones, J. K., 1581
Jones, M. N. A., 268
Joslin, C. E., 1998
Jun, A. S., 279

K

Kaback, M., 1728
Kagemann, L., 782
Kagemann, L. E., 673
Kaiser, P. K., 1366, 2221
Kaiserman, I., 1525
Kakimaru-Hasegawa, A., 988
Kalyan, D. N., 738
Kalyvianaki, M. I., 2174
Kamei, M., 1571
Kampougeris, G., 993
Kamppeter, B. A., 1372
Kane, S. A., 1222
Kang, J. H., 2132
Kang, S. H., 2132
Kanthan, G., 1693
Kanthan, G. L., 808
Kaplan, H. J., 2199
Kaplowitz, K., 347
Karatza, E. C., 1626
Kardon, R. H., 904
Karp, C. L., 51, 1291, 1303
Kashiwagi, K., 1720
Kashkouli, M. B., 1608
Kass, M. A., 1550
Kasza, K., 553
Kato, N., 839
Kato, T., 1376
Katsoulakis, N. P., 573
Katz, J., 1786, 1796, 1809
Katz, L. M., 11
Kaufman, H. E., S1
Kaufman, S. C., S24 S33, 2301
Kawasaki, R., 1376, 1735
Kawasaki, S., 292
Kawata, S., 1376
Kayama, T., 1376
Kaye, S. B., 268
Keane, P. A., 2206
Kearns, L. S., 1053
Keay, L., 1655
Kedhar, S. R., 1826
Kelly, J. P., 390
Kelman, S. E., 1809
Keunen, J. E. E., 870
Keyl, P. M., 1809
Khan, A. O., 730, 2262, 2286
Khan, I., 993
Khanifar, A. A., 1883
Kheirkhah, A., 67
Khurana, R. N., 1237
Kifley, A., 678, 1279
Kiilgaard, J. F., 700
Kijlstra, A., 312
Kikkawa, D. O., 744
Kim, D. M., 2132
Kim, D. Y., 1222
Kim, E. E., 1320
Kim, I. K., 1209
Kim, J. M., 2132
Kim, J. W., 1398
Kim, S. J., 566
Kim, S. K., 483
Kim, S. S., 1699
Kim, T.-W., 2132
Kim, Y. R., 1766
King, A. J. W., 1148
Kinoshita, S., 292
Kishi, S., 718
Kita, M., 355
Kitaguchi, Y., 1771
Kitzmann, A. S., 169
Klein, B. E. K., 477, 1203, 1460, 1742, 1859
Klein, M. L., 876, 1019, 1026
Klein, R., 116, 477, 1203, 1460, 1742, 1859
Kleinmann, G., 73
Knox, A., 1046
Knudtson, M. D., 1203, 1460, 1742, 1859
Kohnen, T., 1308
Koizuma, N., 292
Kollman, C., 1366
Konstas, A. G. P., 99, 1117
Koreishi, A., 1303
Koreishi, A. F., 1291
Koreishi, A. F., 1883
Korn, B. S., 744
Koseki, N., 2049
Kosmorsky, G. S., 560
Kostense, P. J., 1679
Kotera, Y., 355
Kounis, G. A., 2174
Kozak, I., 319
Kozobolis, V. P., 99
Krestin, G. P., 887
Krueger, R. R., 1187
Kruft, B., 1117
Ku, J. Y. F., 845
Kumar, H., 2141
Kumar, R. S., 430, 769, 1167
Kumaramanickavel, G., 648, 655
Kuo, A., 553
Kuper, H., 969
Kurup, S. K., 174
Kusaka, S., 1571
Kutzbach, B. R., 1805
Kwong, Y. Y. Y., 1134, 2167
Kymes, S. M., 898
Kymionis, G. D., 1303, 2174

L

la Cour, M., 700
Labbé, A., 1154
Lade, R. J., 2192
Lai, J. E., 1297
Lai, J. S. M., 2167
Lai, R. Y. K., 1756
Lai, T. Y. Y., 1756
Lalwani, G. A., 473
Lam, A., 80
Lam, D. S. C., 796, 1134, 1347, 1756, 2167
Lam, S. W., 2167
Lamoureux, E. L., 1973
Lan, Y.-W., 1328
Landers, J., 26

Landry, T. A., 1728
Langan, L., 993
Langenberg, P., 1809
Langston, R. H. S., 1540
LaRowe, T. L., 876
Larrosa, J. M., 775
Latkany, P., 553
Lavanya, R., 430, 769, 1720
Leder, H. A., 1826
Lee, A., 808
Lee, A. G., 904, 1426
Lee, B. S., 898
Lee, J., 1196
Lee, K. E., 477, 1203, 1460, 1859
Lee, M. L., 1951
Lee, M. S., 1540
Lee, N., 993
Lee, P., 738
Lee, P. P., 1109, 1315, 1645
Lee, P.-S., 2024
Lee, S. Y., 566
Lee, S. C., 1766
Lempert, P., 2259
Leske, D. A., 371
Leske, M. C., 85, 1557, 2044, 2153
Leung, C. K. S., 796, 1347
Leung, D. Y. L., 1134, 2167
Levin, L., 1809
Levkovitch-Verbin, H., 104
Lévy-Gabriel, C., 1405
Lew, H., 566
Li, C., 1620
Li, F. C. H., 1134, 2167
Li, G., 949
Li, H., 796
Li, N., 830
Li, Y., 2159
Liakopoulos, S., 2206
Liang, H., 109
Liang, K. J., 1957
Liang, Y. B., 1965
Lichter, P. R., 927
Lieberman, M. F., 1557
Liesegang, T. J., S3
Liew, G., 1951
Lim, K. S., 790
Lim, L. S., 975
Lim, S. C., 1869
Lin, C.-J., 2229
Lin, D., 1347
Lin, M., 2290
Lin, S. C., 440, 1089, 1550
Lindblad, B. E., 1687
Lindeman, M., 723
Liu, C., 1162, 1876
Liu, C., 503
Liu, C. J., 1334
Liu, D. T. L., 1756
Liu, K., 1742
Liu, Y., 830
Liu, Y. I., 2013
Lodato, G., 1508
Loiacono, C., 1534
Long, J. A., 1241
Lonser, R. R., 1382
Loon, S.-C., 964
Los Angeles Latino Eye Study Group, 227, 639, 815, 941
Lu, A. T. H., 2159
Lu, A. T.-H., 949, 1352
Ludlow, S. E., 2235
Lum, F., 225, 1591, 2125
Luyten, G. P. M., 608
Lye, K.-W., 503
Lynn, M. J., 37

M

Ma, P. E., 1944
Maberley, D. A., 1944
MacDonald, J. T., 1805
Mackey, D. A., 1053, 1545
MacKinnon, J. R., 1053
MacLaren, R. E., 1705
Maddison, P. G., 253
Mader, T. H., 377
Maguire, M. G., 1468, 1876
Mahendradas, P., 287
Majmudar, P. A., 1249
Makridaki, I., 99
Males, J., 268
Maling, S., 993
Maloney, R. K., 464
Manchandia, A., 1673
Mandel, Y., 686
Manero, F., 1002
Manni, G., 1358
Mares, J. A., 876
Margolis, J. W., 1591
Marr, B. P., 511
Martin, N. G., 1053
Mashayekhi, A., 511, 546
Mathew, M. R. K., 1411
Matoba, A. Y., 866
Matsumoto, Y., 2004
Matsumura, M., 1916
Matsunaga, N., 1916
Mawn, L. A., 1620
Mazhar, K., 815
McAllum, P., 1525
McCarty, C., 648, 655
McFadzean, R. M., 1411
McGhee, C. N. J., 845
McGwin, G., 447, 1241
McKean-Cowdin, R., 941
McLaren, J. W., 790
McLeod, R., 553
McMahon, J. T., 1540
McNaught, A., 2058
Medeiros, F. A., 934, 1340
Meier, P., 553
Meisler, D. M., 1540, 2159
Melamed, S., 104
Meligonis, G., 386, 1989
Meng, Q., 312
MEPEDS Study Group, 1422
Mester, U., 1308
Mets, M., 553
Meyer, B., 730
Meyer, D. R., 398, 1083
Meyerle, C. B., 1382
Meyers, S., 553
Michalova, K., 1911
Mieler, W., 553
Mihashi, T., 1771
Miki, A., 1571
Miller, D., 51, 473, 1501
Miller, J. W., 1209
Min, Y. H., 1766
Minassian, D., 1647
Minckler, D. S., 1089
Missotten, G. S., 195
Mitchell, P., 116, 334, 678, 693, 808, 1273, 1279, 1376, 1693, 1713 1735, 1869, 1891, 1951
Miyamoto, K., 355
Miyazaki, D., 988
Mizuno, S., 147
Mizutani, Y., 2215
Mochida, C., 292
Mochizuki, M., 708
Mohebbi, M. R., 1938
Mohney, B. G., 371
Montague, A., 2013
Montgomery, G. W., 1053
Moore, E., 1203
Morgan, I. G., 1279
Morgan, J. E., 2058
Mori, R., 2215
Moriyama, M., 708
Morlet, N., 3
Moroi, S. E., 925
Morral, M., 1002
Morreale, R., 1508
Morrison, M. A., 1209
Morse, L. S., 1923
Morton, A. P., 3
Moss, J. M., 2013
Motsko, S. P., 1581
Much, J. W., 1162
Muecke, J., 26
Muftuoglu, O., 57
Mulder, P. G. H., 608
Multi-ethnic Pediatric Eye Disease Study Group, 1229
Mumcuoglu, T., 782
Murray, T. G., 473
Murthy, R., 1608
Murube, J., 262
Musch, D. C., 927, 2295, 2301
Müskens, R. P. H. M., 2037
Mutani, B., 1534
Mychaskiw, M. A., 94

N

Naduvilath, T., 1655
Nagahara, M., 2049
Nagata, Y., 988
Nakashizuka, H., 2215
Nakazawa, N., 1771
Nambiar, A., 455
Narayana K. M., 287
Nassar, Q. J., 94
Nau, C. B., 790
Nease Jr, R. F., 898
Nelson, C. C., 2295
Nelson, L. A., 1117

Nemesure, B., 85, 2153
Neuhann, I. M., 73
Newland, H. S., 26
Ng, J. Q., 3
Nguyen, D., 2013
Niederer, R. L., 845
Nishimuta, A., 708
Nitsch, D., 1904
Niziol, L. M., 927
Noble, A. G., 553
Nolan, W., 2024
Noordzij, B., 608

O

Obana, A., 147
O'Brien, T. P., 1303, 1517, 2181
O'Byrne, M. M., 790
Ocular Hypertension Treatment Study Group, 1550, 2030
Oddone, F., 1358
Odel, J. G., 904
Ogata, N., 1916
Ohashi, Y., 292
Ohira, A., 147
Ohji, M., 141
Ohno-Matsui, K., 708
Oizumi, T., 1376
Okamoto, C., 1216
Okamoto, F., 1216
Oldfield, E., 1382
Olsen, T. W., 1891
Ong, E. L., 2024
Optic Neuritis Study Group, 1079
Ortiz, S., 1245
Oshika, T., 1216
Oshima, Y., 141, 1571
Ota, M., 355
Otori, Y., 1571
Ott, J., 1019, 1209
Owen, C. G., 1089
Owen, R. I., 525
Oystreck, D. T., 1800, 2262, 2286

P

Pablo, L. E., 775
Pajarín, A. B., 775
Pakravan, M., 425
Pallikaris, I. G., 2174
Panagopoulou, S. I., 2174
Pang, C. P., 796
Pang, C.-P., 1347
Papchenko, T., 1566
Parbhu, K. C., 1620
Parekh, P., 614
Paridaens, D., 189
Parikh, J. G., 1237, 1833
Parikh, R. S., 1167
Parikh, S. R., 1167
Parisi, V., 324, 1489
Park, K. H., 2132
Park, S., 525
Park, S. S., 1923
Parthasarathy, A., 503
Pasquale, L. R., 246, 633, 761
Patel, D. V., 845
Pavan-Langston, D., S13 S21
Pediatric Eye Disease Investigator Group, 577, 2071, 2263
Pedroza, C., 1058
Peet, J., 1039
Pericak-Vance, M. A., 520
Peters III, G. B., 1826
Peto, T., 700
Phan, A.-D. T., 1141
Phan, L., 511, 553
Philipson, B., 1687
Phillips, M., 253
Piermarocchi, S., 324
Pillitteri, F., 1508
Piltz-Seymour, J. R., 1162
Pirondini, C., 2246
Piva, A. P., 1613
Polak, B. C. P., 1679, 2017
Polat, U., 686
Pollack, J. S., 884
Polo, V., 775
Poon, A. S. Y., 2167
Poostchi, A., 667
Por, Y.-M., 503
Porciatti, V., 957
Postel, E. A., 520
Postma, G., 306
Poulson, A. V., 164
Prabakaran, S., 1167
Prakalapakorn, S. G., 2065
Prause, J. U., 700
Price Jr, F. W., 857
Price, M. O., 857
Probst, C., 116
Pulido, J. S., 169
Punjabi, O. S., 440

Q

Qin, H., 1366
Quigley, H. A., 239, 1320
Quinn, C. M., 473
Quinn, G. E., 1058
Qureshi, S., 1911

R

Rabiah, P., 553
Radford, C. F., 1647
Rahi, J. S., 1013
Rajan, M. S., 1989
Raju, P., 648, 655
Ramesh, S. V., 648
Ramezani, A., 1938
Ramsay, A., 253
Randleman, J. B., 37, 2181
Ranganna, S. K., 287
Rao, N. A., 1237, 1833
Rao, S. K., 573
Rauz, S., 253
Recchia, F. M., 1837
Reed, G. F., 181, 1891
Reinhart, W. J., 2301
Reinke, J. O., 1203
Reiser, B. J., 2159
Remington, J., 553
Ren, Y., 312
Repka, M. X., 1786, 1796
Reynolds, R., 1019
Riancho, L., 109
Richards, A. B., 2282
Richards, A. J., 164
Richiardi, L., 1534
Ringens, P. J., 1679, 2017
Ripandelli, G., 1489
Ritchey, J. P., 377
Rivas, L., 262
Robaei, D., 678
Rochtchina, E., 334, 808, 1693
Rodriguez-Coleman, H., 1382
Roh, S., 447
Roizen, N., 553
Romano, P. W., 347
Rootman, D., 1525
Rootman, D. S., 1130
Rose, G. E., 386
Rose, K. A., 678, 1279
Rose, L., 279
Rosenberg, T., 700
Rosner, B., 1019
Ross, R. J., 693, 1891
Rossetti, L., 1358
Rotchford, A. P., 1148
Rothova, A., 306, 2062
Rouic, L. L., 1405
Rouleau, J., 904
Rubin, G. S., 1480
Ruby, A. J., 884
Ruddle, J. B., 1053
Ruiz Jr, D., 1109

S

Saad, M. F., 1742
Sachdev, N., 667
Sachs, D., 104
Sacu, S., 134
Sadda, S., 1366
Sadda, S. R., 347, 2206
Saito, H., 1585
Sakaguchi, H., 141, 1571, 1771
Sakai, C., 839
Sakamoto, A., 355, 1071
Sakata, L. M., 430, 769, 1720
Salem, C., 1728
Salih, M. A., 2286
Sample, P. A., 934, 1340
Samples, J. R., 1089
Sandar, M., 1713, 1735
Sarrafizadeh, R., 884
Sastre, X., 1405
Satoh, T., 1982
Saw, S. M., 1869
Saw, S.-M., 802, 964, 1713, 1735, 1973
Saw, V. P. J., 253
Sawa, M., 141, 1494
Sawada, A., 363
Saxena, R., 608
Sayanagi, K., 141
Schaal, S., 2199
Schachat, A. P., 1032, 1443, 1445
Schallhorn, S. C., 1249
Schaumberg, D. A., 1982

Schechter, B. A., 1291
Scherer, R. W., 1809
Schmack, I., 2181
Schmidt, G. W., 202
Schmidt, S., 520
Schmidt-Erfurth, U., 134
Schneider, M., 2062
Schneiderhan-Marra, N., 1750
Schoenfield, L., 1540
Schuller, M., 306
Schultz, D. W., 1019
Schuman, J. S., 673, 782, 1352
Scoper, S. V., 1728
Scott, I. U., 473, 573, 1366, 1501, 1837
Scott, J. D., 164
Scott, K. E., 1222
Scott, W. K., 520
Seah, S. K., 1720
Secker, G. A., 1989
Seddon, J. M., 1019
Seidahmed, M. Z., 2286
Seiple, W., 723
Selva, D., 26
Semmens, J. B., 3
Shah, S. N., 1320
Shamie, N., 488, 497, 1179
Shankar, A., 1713
Shao, C., 2290
Sharma, S., 2221
Sharrett, A. R., 1742
Shaw, A., 1608
Shen, S. Y., 964
Sherwin, T., 845
Shetty, B. K. 287
Shetty, R., 287
Shi, W., 33, 983, 1699
Shields, C. L., 511, 546, 1626, 1673, 2246, 2253
Shields, J. A., 511, 546, 1626, 1673, 2246, 2253
Shih, Y.-F., 734
Shimada, H., 2215
Shimada, N., 708
Shimazaki, J., 851
Shimazawa, M., 1916
Shimmura, S., 851, 1982
Shiraishi, A., 292
Shoeibi, N., 1938
Shoff, M. E., 1998
Shome, D., 483
Shortt, A. J., 1989
Shuler Jr, R. K., 520
Siegfried, C. J., 898
Singapore Malay Eye Study Group, 964, 1735
Singh, K., 1089, 2013
Sisquella, M., 1002
Slade, C. S., 377
Sledge, I., 116
Sloan, F. A., 1109, 1315
Slomovic, A., 1525
Slomovic, A. R., 1130
Sloper, J. J., 1930
Smeeth, L., 1904
Smiddy, W. E., 473, 1699
Smith, A. J., 1923
Smith, S. D., 423, 1089, 1352
Smith, W., 334, 1279
Smolinski, P., 174
Snead, M. P., 164
Snodderly, D. M., 876
Sobrin, L., 1416
Solomon, S. D., 1032
Sommer, A., 1, 2125
Song, C. D., 483
Song, W. K., 1766
Sonmez, K., 1065
Sotozono, C., 292
Spector, T. D., 1545
SPR Study Group, 1635
Srinivasan, V., 782
Stamper, R. L., 440
Stapleton, F., 1647, 1655
Stark, W. J., 279, 614
Starren, J., 1222
Steel, D. H. W., 525
Stein, J. D., 1109, 1315
Steinert, R. F., 1196
Stern, L. S., 11, 633
Stewart, J. A., 94
Stewart, W. C., 94, 99, 1117
Stinnett, S., 738
Stirpe, M., 1489
Stricker, B. H. C., 2037
Strobel, J., 1308
Stulting, R. D., 37, 464, 2181
Stumpf, T. H., 2058
Sturges, A., 1297
Stutzman, R. D., 377
Su, D. H. W., 964
Su, W.-W., 1173
Subbiah, R., 1673
Submacular Surgery Trials Research Group, 127
Sugar, A., 1249
Sugar, J., 1998
Suh, D. W., 1800
Suh, L. H., 1517
Summers, C. G., 1805
Sumner, W., 898
Sun, F.-J., 1328
Sun, L. P., 1965
Sun, S., 983
Sunness, J. S., 1480
Suzuki, T., 292
Sweeney, M. O., 1209
Swisher, C., 553
Szlyk, J. P., 723
Szurman, P., 1750

T

Ta, C. N., 2013
Taban, M., 2221
Tabatabaei, H., 1938
Tai, E. S., 1869
Tajimi Study Group, 363
Takebayashi, T., 1982
Taktak, A. F. G., 1598
Tamaki, Y., 2049
Tammewar, A. M., 319
Tan, A. G., 693, 808, 1693
Tan, D. T. H., 503, 964, 975, 1713, 1735
Tan, J., 1320
Tan, J. S. L., 334
Tan, O., 949
Tan, Y., 1566
Tang, M., 2159
Tanito, M., 147
Tano, Y., 141, 1376, 1494, 1571, 1771
Tanzer, D. J., 1249
Tarczy-Hornoch, K., 1422
Tatar, O., 1750
Tawansy, K. A., 1833
Tay, A. B. G., 503
Tay, W. T., 1869
Taylor, B., 1376, 1951
Teasdale, E., 1411
Tedeschi, M., 324
Telander, D. G., 1923
Terry, M. A., 488, 497, 1179
Tezel, T. H., 2199
Thach, A. B., 377
Thakrar, V., 2159
Tham, C. C. Y., 1134, 2167
Thangappan, A., 511, 2246, 2253
Theelen, T., 870
Theng, J. T. S., 503
Thomas, M. A., 540
Thomas, R., 1167
Thompson, V. M., 464
Thorne, J. E., 1826, 2146
Thornton, I. L., 1187
Thumboo, J., 1973
Tielsch, J. M., 1786, 1796
Tikellis, G., 1951
Toda, I., 839
Tokoro, T., 708
Tole, D. M., 268
Tomidokoro, A., 363, 1585, 2049
Tominaga, T., 988
Tomita, G., 1585
Tomita, M., 851
Toris, C. B., 790
Torres, M., 227
Toth, C. A., 1883
Tousi, A., 425
Toxoplasmosis Study Group, 553
Tran, T., 181
Trattler, W. B., 1249
Trent, J., 483
Trese, M. T., 1065
Trope, G. E., 1130
Tsay, P.-K., 1173
Tseng, L.-F., 2229
Tsironi, S., 99
Tsubota, K., 839, 851, 1982, 2004
Tsujikawa, A., 355
Tsujikawa, M., 1494
Tu, E. Y., 1998
Tübingen Bevacizumab Study Group, 1750
Tuft, S. J., 1989
Tuncer, S., 2253
Tung, B., 1058
Tuo, J., 693, 1891
Turco, D., 1534

U

Uchino, M., 1982
Uchino, Y., 1982
Udell, I. J., 2301
Uitterlinden, A. G., 1899
UK Transplant Ocular Tissue Advisory Group and Contributing Ophthalmologists, 268
Uno, T., 292
Updike, P. G., 347
Uranchimeg, D., 2024
U.S. Verisyse Study Group, 464

V

Vajaranant, T. S., 723
Valente, P., 2246
Valldeperas, X., 158
van den Berg, T. J.T.P., 1187
van den Bosch, W. A., 189
van der Lugt, A., 887
van Duijn, C. M., 1899
van Loon, A. M., 306
van Rij, G., 608
Van Meter, W. S., 2301
Varano, M., 324
Varma, R., 227, 639, 815, 941, 949, 1352, 1422, 1857
Vasile, C., 934
Ve Ramesh, S., 655
Ventura, A. A. C. M., 2221
Verity, D. H., 386
Verma, S., 1647
Vernooij, M. W., 887
Vicinanzo, M. G., 1241
Vijaya, L., 648, 655
Vingerling, J. R., 1899
Vizzeri, G., 1340
Vujosevic, S., 342

W

Wade, N. K., 1944
Wakabayashi, T., 1494, 1571
Wakakura, M., 1585
Wallace, D. K., 1271
Walsh, A. C., 347, 2206
Walt, J. G., 11, 633
Wang, F. H., 1965
Wang, I., 1328
Wang, J. J., 334, 678, 693, 808, 1273, 1376, 1693, 1735, 1869, 1891 1951, 1965, 1973
Wang, L., 1222
Wang, M., 1237, 1352, 2206
Wang, N. L., 1965
Wang, Y., 941, 1422
Warnet, J.-M., 109
Wealti, A. M., 1203
Wee, H. L., 1973
Weersink, A. J. L., 306
Wei, M., 830
Weichel, E. D., 2087, 2235
Weinreb, R. N., 796, 934, 1340
Weiss, A. H., 390
Wells, A. P., 667
Wenick, A. S., 904
Wentzloff, J. N., 633
Werner, J. S., 1923
West, S. K., 233
Wetjen, N. M., 1382
White, V. A., 1944
Wickremasinghe, S. S., 1911
Wiemer, N. G. M., 1679, 2017
Wilhelmus, K. R., 866
Willemsen, M. A. A. P., 870
Williams, A., 693
Williams, G. A., 884
Williams, M. A., 276
Wilson, M. C., 1426
Wilson, P. D., 1809
Witteman, J. C. M., 2037
Wittenberg, L. A., 1944
Wojtkowski, M., 782
Wolfs, R. C. W., 2037
Wolk, A., 1687
Wollstein, G., 673, 782
Wong, D., 158
Wong, H.-T., 430
Wong, L., 796
Wong, S. C., 1705
Wong, T., 116, 667
Wong, T. Y., 597, 802, 964, 1376, 1713, 1735, 1742, 1869, 1911, 1951, 1965, 1973
Wong, T.-Y., 1720
Wong, W.-L., 964, 1713
Wong, W. T., 181, 1382, 1957
Woodside, J. V., 1046
Woodward, M., 37
Woog, J. J., 398
Wooten, B. R., 876
Woreta, F. A., 2146
Wu, J., 227, 815, 941
Wu, M., 969
Wu, S.-C., 1173
Wu, S.-Y., 85, 2153
WuDunn, D., 1141
Wykoff, C. C., 1501

X

Xie, L., 33, 983
Xing, L., 312
Xing, W., 253
Xu, M., 1187
Xu, X., 1750

Y

Yamaguchi, T., 1771
Yamaike, N., 355
Yamamoto, S., 2049
Yamamoto, T., 363
Yamane, N., 1216
Yamasaki, K., 292
Yamashita, H., 1376
Yan, Q., 1891
Yang, C.-H., 734
Yang, C.-M., 734
Yang, P., 312
Yang, X. H., 1965
Yang, Z., 2044
Yao, X., 830
Yazdani, S., 425
Yeh, P.-T., 734
Yick, D. W. F., 2167
Ying, G., 1876
Ying-Lai, M., 639
Yip, J. L. Y., 969
Yoo, S. H., 1303, 1517
Yoon, J. S., 566
Yoshida, T., 708
Yoshimura, N., 355, 1071
Yu, F., 18
Yuzawa, M., 2215

Z

Zack, B., 1130
Zahler, J. D., 546
Zang, X., 983
Zangwill, L. M., 934, 1340
Zawadzki, R. J., 1923
Zhai, H., 983
Zhan, S. Y., 1965
Zhang, J., 830
Zhang, L., 239
Zhang, Y. P., 1951
Zhao, J., 983
Zheng, Y., 1286
Zhou, H., 975, 2290
Zhou, Q., 1965
Zhou, Y., 830
Zhu, G., 1053
Zhu, H., 2290
Zhu, Q., 1750
Ziemssen, F., 1750
Zimmerman, M. B., 298, 1818, 2275
Zimmerman, T. J., 1320
Zlateva, G., 116
Zutshi, D., 51
Zuurveen, S. J., 306

Subject Index to Volume 115

January	pages 1–224	July	pages 1107–1270
February	pages 225–422	August	pages 1271–1442
March	pages 423–596	September	pages 1443–1644
April	pages 597–760	October	pages 1645–1856
May	pages 761–924	November	pages 1857–2124
June	pages 925–1106	December	pages 2125-2358

A

Abdominal adiposity, metabolic syndrome components and risk of cataract extraction in women, 1687
Acanthamoeba keratitis
  cataract and iris atrophy during treatment of, 866
  prognostic factors affecting visual outcome in, 1998
Acute retinal necrosis
  in Japan *(Letter)*, 1632
  (Letter), 1104
Adaptive optics images of localized photoreceptor changes, 1771
Adverse drug effects
  amantadine-associated corneal edema, 1540
  diplopia, blepharoptosis, ophthalmoplegia and statin use, 2282
  inflammation after intravitreous bevacizumab injections for neovascular AMD, 1911
  ptosis after sub–Tenon's capsule triamcinolone *(Letter)*, 410
  reflux after intravitreal injection of bevacizumab *(Letter)*, 1268
  topical β-blockers and mortality, 2037
  ulcerative keratitis in GIST patients treated with perifosine, 483
Age/aging
  age-related changes of meibomian glands, 911
  refraction and *(Letter)*, 2097
  supplements and age-related eye conditions, 1203
  ten-year incidence of age-related cataract and cataract surgery in Australian population, 808
  vitamin E and age-related cataract in randomized trial of women, 822
Age-related macular degeneration (AMD)
  anti-VEGF pharmacotherapy for *(Ophthalmic Technology Assessment)*, 1837
  autofluorescence imaging in AMD with choroidal neovascularization, 342
  Beaver Dam Eye Study, age–period–cohort effect on incidence of AMD, 1460
  CFH and *LOC387715/ARMS2* genotypes and treatment with antioxidants and zinc for, 1019
  complement activation–related diseases and, 1904
  Complications of Age-related Macular Degeneration Prevention Trial, night vision symptoms and progression of AMD, 1876
  cost-utility analysis for treatment of, 2192
  dietary antioxidants and long-term incidence of, 334
  drusen ultrastructure imaging with spectral domain OCT in, 1883
  eye-related Medicare costs for patients with AMD 1995–1999, 18
  genetics of *(Letter)*, 916
  HtrA1 promfoter polymorphism, smoking, and AMD, 1891
  inflammation, complement factor H and, 1742
  LOC387715 polymorphism, inflammatory markers, smoking and, 693
  low luminance function and geographic atrophy in, 1480
  neovascular
    alleles in HtrA serine peptidase 1 gene and risk of, 1209
    characteristics of choroidal neovascularization, 1468
    inflammation after intravitreous bevacizumab injections for, 1911
    more intense vs. standard early verteporfin treatment, 134
    natural history and prognosis for, 116 (erratum, 1524)
    OCT after pegaptanib or bevacizumab in, 347
    OCT retinal parameters and visual acuity in, 2206
    risk factors for choroidal neovascularization and geographic atrophy, 1474
    vitreous levels of bevacizumab and VEGF-A in, 1750
  one-year results of PDT in AMD and polypoidal choroidal vasculopathy in Japanese patients, 141
  peripheral reticular pigmentary change and complement factor H Y402H variant in, 520
  prevalence and risk factors in adult Japanese population, 1376
  prevalence in Malay population, 1735
  prevalence of ARM and AMD among Inuit in Greenland, 700
  progress toward personalized medicine for *(Editorial)*, 925
  retinal precursors and development of geographic atrophy in, 1026
  Rotterdam Study, VEGF gene polymorphisms and AMD risk, 1899
  supplements and, 1203
  tachyphylaxis to intravitreal anti-VEGF therapy in, 2199
  vitamin usage patterns in prevention of advanced AMD, 1032
Age-related maculopathy (ARM)
  carotenoids and antioxidants in, 324
  macular carotenoid levels in Japanese patients with, 147
  macular pigment density and, 876
  prevalence of ARM and AMD among Inuit in Greenland, 700
Airbag deployment, seatbelt use, and ocular injuries, 573
Albinism
  foveal depression and *(Letter)*, 756
  neurodevelopment in children with, 1805
Alemtuzumab, CMV retinitis after hematopoietic stem cell transplantation with, 1766
Amantadine-associated corneal edema, 1540
Amblyopia
  near vs. far distance activities while patching for, 2071
  retinal area/optic disc rim area ratio in, 2259
  and strabismus in African American and Hispanic children, 1229
AMD. *See* Age-related macular degeneration
American Academy of Ophthalmology
  adoption of SNOMED CT as official clinical terminology *(Editorial)*, 225
  anti-VEGF pharmacotherapy for AMD *(Ophthalmic Technology Assessment)*, 1837
  aqueous shunts in glaucoma *(Ophthalmic Technology Assessment)*, 1089
  independent auditors' report and consolidated financial statements, 2101
  safety of overnight orthokeratology for myopia *(Ophthalmic Technology Assessment)*, 2301
  survey of adoption and perceptions of electronic health record systems by ophthalmologists, 1591
  wavefront-guided LASIK for correction of primary myopia and astigmatism *(Ophthalmic Technology Assessment)*, 1249

Anatomy, functional, of inferior rectus muscle in superior oblique muscle palsy, 2079
Anesthesia
for phacotrabeculectomy *(Letter)*, 752
supplementary intracameral lidocaine for phacoemulsification under topical anesthesia, 455
Angle-closure, mydriasis-induced *(Letter)*, 1434
Aniridia
autologous serum eyedrops in aniridic keratopathy, 262
implantation of black diaphragm IOL in, 1705
Anisocoria, episodic, and anxiety *(Letter)*, 1262
Anisometropia, prevalence and risk factors in Singapore Malay Eye Study, 1713
Anterior chamber
depth in elderly Chinese, 1286
gonioscopy vs. anterior segment OCT in detecting angle closure in different quadrants of anterior chamber angle, 769
retained lens fragments in *(Letter)*, 414
Anti-inflammatory therapy, mycophenolate mofetil after methotrexate for scleritis and uveitis, 1416
Antihypertensive therapy
cost-effectiveness of treating ocular hypertension, 94 (erratum, 1524) *(Letter)*, 1433
doctor–patient communication, health-related beliefs, and adherence in glaucoma, 1320
mechanism of action of bimatoprost, latanoprost, and travoprost, 790
meta-analysis of 24-hour IOP studies evaluating efficacy of glaucoma medications, 1117
ocular surface of treated glaucoma patients expresses CCR5 and CCR4, 109
rates of glaucoma medication utilization in primary open-angle glaucoma, 1315
topical β-blockers and mortality, 2037
24-hour IOP-lowering effects of latanoprost vs. dorzolamide/timolol, 99
Antimetabolite drugs for noninfectious ocular inflammation, 1826
Antimicrobial therapy
moxifloxacin for bacterial keratitis *(Letter)*, 1103
one-day vs. one-hour application of topical gatifloxacin in eliminating conjunctival bacterial flora, 2013
Antioxidants
and carotenoids in ARM, 324
CFH and *LOC387715/ARMS2* genotypes and treatment with antioxidants and zinc for AMD, 1019
dietary, and long-term incidence of AMD, 334
multivitamin supplementation for age-related lens opacities, 599
multivitamin supplements and cataract prevention *(Editorial)*, 597
vitamin E and age-related cataract in randomized trial of women, 822
vitamin usage patterns in prevention of advanced AMD, 1032
Anxiety, episodic anisocoria and *(Letter)*, 1262
Aqueous humor
analysis for diagnosis of posterior uveitis, 306
filtering blebs and aqueous pathway, 1154
Aqueous misdirection syndrome, transscleral cyclodiode laser photocoagulation in, 2058
Aqueous shunts in glaucoma *(Ophthalmic Technology Assessment)*, 1089
ARM. *See* Age-related maculopathy
Artisan phakic IOL
3-year results after implantation of, 464
endothelial cell loss after implantation of, 608 *(Letter)*, 753
Asian populations
acute retinal necrosis in Japan *(Letter)*, 1632
anterior chamber depth in elderly Chinese, 1286
Behçet's disease in Chinese patients, 312
choroidal nevi in adult Chinese *(Letter)*, 1102
dry eye disease among Japanese visual display terminal users, 1982
early phacoemulsification vs. peripheral iridotomy to prevent IOP rise after acute primary angle closure, 1134
guidelines for PDT in Japan *(Letter)*, 585
Handan Eye Study, low vision and blindness in rural Chinese adults, 1965
keratoprosthesis surgery for end-stage corneal blindness in, 503
macular carotenoid levels in Japanese ARM patients, 147
one-year results of PDT in AMD and polypoidal choroidal vasculopathy in Japanese patients, 141
prevalence and risk factors for AMD in adult Japanese population, 1376
rapid assessment of avoidable blindness in Kunming, China, 969
refractive error in Myanmar *(Letter)*, 1642
refractive errors in elderly Japanese population, 363
screening for narrow angles in Singapore population, 1720
Singapore Corneal Transplant Study, PK in Asian eyes, 975
Singapore Malay Eye Study
diabetes, hyperglycemia, and central corneal thickness, 964
prevalence and risk factors for diabetic retinopathy, 1869
prevalence and risk factors for refractive errors in, 1713
prevalence of AMD in, 1735
vision impairment, ocular conditions, and vision-specific function, 1973
ultrasound biomicroscopy study of plateau iris in primary angle closure subjects, 430
visual acuity and mortality in Chinese population, 802
Astigmatism
evaluation of internal refraction with optical path difference scan, 57
five-year follow-up of 399 Artisan–Verisyse phakic IOLs for, 1002
induced by periocular capillary hemangioma, intralesional corticosteroids for, 390
periocular hemangioma and *(Letter)*, 1854
prevalence and risk factors in Singapore Malay Eye Study, 1713
wavefront-guided LASIK for correction of primary myopia and astigmatism *(Ophthalmic Technology Assessment)*, 1249
Atopic keratoconjunctivitis, corneal in vivo confocal scanning laser microscopy in, 2004
Atopic sclerokeratitis, postkeratoplasty, in keratoconus patients, 851
Autofluorescence imaging
in AMD with choroidal neovascularization, 342 *(Letter)*, 1853
Autologous serum eyedrops, in aniridic keratopathy, 262
Azathioprine, for noninfectious ocular inflammation, 1826

B

Baltimore Pediatric Eye Disease Study
low concordance of fixation preference with visual acuity in preschool children, 1796
prevalence of decreased vision in preschool-aged children, 1786
Barbados Eye Studies
pterygium incidence and risk factors in, 2153
risk factors for incident open-angle glaucoma, 85
Beaver Dam Eye Study
age–period–cohort effect on incidence of AMD, 1460
incidence of age-related cataract over 15-year interval, 477
supplements and age-related eye conditions, 1203
Behçet's disease, in Chinese patients, 312
Bevacizumab
anti-VEGF pharmacotherapy for AMD *(Ophthalmic Technology Assessment)*, 1837
inflammation after intravitreous injections for neovascular AMD, 1911
intravitreal, to treat iris neovascularization and neovascular glaucoma, 1571
macular edema and *(Letter)*, 585

OCT after pegaptanib or bevacizumab in neovascular AMD, 347
reflux after intravitreal injection of *(Letter)*, 1268
subconjunctival, as adjunct to trabeculectomy, 2141
tachyphylaxis to intravitreal anti-VEGF therapy in AMD, 2199
vitreous levels of bevacizumab and VEGF-A in choroidal neovascularization, 1750
Bias and sponsored research *(Letter)*, 412
Bimatoprost
mechanism of action, 790
meta-analysis of 24-hour IOP studies evaluating efficacy of glaucoma medications, 1117
Binocular vision, after surgery to remove a unilateral epiretinal membrane, 1930
Biomaterials. *See also* Intraocular lens
double silicone tube intubation for partial lacrimal system obstruction, 383
exposure rate of hydroxyapatite implants over 15 years, 566
hydroxyapatite orbital implants *(Letter)*, 2096, 2320
intraorbital hyaluronic acid for enophthalmos *(Letter)*, 1101
premature silicone stent loss after dacryocystorhinostomy, 1241
Bitemporal hemianopsia, nonuniform pressure generation in, 560
Blebs
aqueous pathway and, 1154
needling revision of trabeculectomy, 1148
Bleeding
disc hemorrhage in primary angle-closure glaucoma, 1328
disc hemorrhages and treatment in Early Manifest Glaucoma Trial, 2044
optic disc hemorrhage associated with RNFL loss, 2132
vitreous cavity hemorrhage after diabetic vitrectomy, 525
Blepharoptosis
statin use, diplopia, ophthalmoplegia and, 2282
after sub–Tenon's capsule triamcinolone *(Letter)*, 410
Blindness. *See* Vision impairment/loss
β-Blockers
IOP-lowering efficacy of brinzolamide and timolol, 1728
meta-analysis of 24-hour IOP studies evaluating efficacy of glaucoma medications, 1117
topical, mortality and, 2037
24-hour IOP-lowering effects of latanoprost vs. dorzolamide/timolol, 99
Blood flow
effect of nilvadipine on visual field and ocular circulation in glaucoma, 2049
oxygen saturation, cerebral blood flow, and retinal vessel diameters, 887
retinal blood flow response to posture change in glaucoma, 246
Blood glucose, intravitreal triamcinolone and *(Letter)*, 916
Blood pressure
association with retinal vasculature as a fractal, 1951
cardiovascular disease, choroidal neovascularization, and hypertension, 1046
metabolic syndrome components and risk of cataract extraction in women, 1687
Blue Mountains Eye Study
dietary antioxidants and long-term incidence of AMD, 334
LOC387715 polymorphism, inflammatory markers, smoking, and AMD, 693
retinal vessel caliber and incidence of age-related cataract, 1693
ten-year incidence of age-related cataract and cataract surgery in Australian population, 808
Body mass index, vein occlusion and *(Letter)*, 917
Brinzolamide, IOP-lowering efficacy of timolol and, 1728
British Congenital Cataract Study, glaucoma after surgery for congenital cataract, 1013
Brown syndrome, surgical outcome of superior oblique tendon suture spacer for, 1800

C

Calcification of IOLs, 73
Carcinosarcoma of orbit, 2065
Cardiovascular disease, hypertension, and choroidal neovascularization, 1046
Carotenoids
and antioxidants in ARM, 324
Carotenoids in Age-Related Eye Disease Study, macular pigment density and ARM, 876
macular levels in Japanese ARM patients, 147
Cataract
cataract and iris atrophy during treatment of *Acanthamoeba* keratitis, 866
identification in patients with neovascular maculopathy, 127
incidence of age-related cataract over 15-year interval, 477
multivitamin supplementation for age-related lens opacities, 599
multivitamin supplements and cataract prevention *(Editorial)*, 597
phacoemulsification vs. combined phacotrabeculectomy in chronic angle closure glaucoma with, 2167
relationship of 10-year change in refraction to nuclear cataract and axial length, 1273
retinal vessel caliber and incidence of age-related cataract, 1693
secondary prevention *(Letter)*, 212
supplements and age-related eye conditions, 1203
ten-year incidence of age-related cataract and cataract surgery in Australian population, 808
vitamin E and age-related cataract in randomized trial of women, 822
Cataract surgery
acute-onset endophthalmitis after (1996–2005), 473
anesthesia for phacotrabeculectomy *(Letter)*, 752
charges for *(Letter)*, 210
comparison of 1-site and 2-site phacotrabeculectomy, 447, 1130
complication rates *(Letter)*, 1432
cost-effectiveness of small-incision surgery *(Letter)*, 211
effect of AcrySof vs. silicone or polymethyl methacrylate IOL on posterior capsule opacification, 830
endophthalmitis after *(Letter)*, 413
glaucoma after surgery for congenital cataract, 1013
IOP elevation within 24 hours in patients with glaucoma or exfoliation syndrome, 104
metabolic syndrome components and risk of cataract extraction in women, 1687
retained lens fragments after *(Letter)*, 414
supplementary intracameral lidocaine for phacoemulsification under topical anesthesia, 455
techniques to monitor for endophthalmitis and other complications of, 3
ten-year incidence of age-related cataract and cataract surgery in Australian population, 808
tip position during phaco *(Letter)*, 2314
in uveitis *(Letter)*, 1431
visual acuity after cataract extraction in adult Latinos, 815
Central corneal thickness
changes over time, 1550
diabetes, hyperglycemia and, 964
measurement with slip-lamp OCT vs. Visante OCT, 796
ultrasound pachymetry and OCT measurements *(Letter)*, 2315
Central retinal vein occlusion (CRVO)
interventions for *(Letter)*, 219
radial optic neurotomy for, 174
radial optic neurotomy *(Letter)*, 1638

Central serous chorioretinopathy
half-dose verteporfin PDT for, 1756
OCT of morphologic changes in, 1494
in Olmsted County, MN, 1980–2002, 169
subthreshold diode micropulse photocoagulation for, 2229
Cerebrospinal fluid (CSF) pressure
decreased, in primary OAG, 763
glaucoma and *(Letter)*, 2316, 2317
low ICP: tipping point in understanding of primary OAG?, 761
Cerebrovascular disease, oxygen saturation, cerebral blood flow, and retinal vessel diameters, 887
Chemokine receptors, ocular surface of treated glaucoma patients expresses CCR5 and CCR4, 109
Chemotherapy
conservative treatments for intraocular retinoblastoma, 1405
intraarterial melphalan for intraocular retinoblastoma, 1398
Chennai Glaucoma Study
prevalence of open-angle glaucoma in South India, 648
prevalence of primary angle-closure glaucoma in South India, 655
Chikungunya, ocular manifestations of, 287
Chinese population
anterior chamber depth in elderly persons, 1286
Behçet's disease in, 312
choroidal nevi in adult Chinese *(Letter)*, 1102
early phacoemulsification vs. peripheral iridotomy to prevent IOP rise after acute primary angle closure, 1134
rapid assessment of avoidable blindness in Kunming, China, 969
Tanjong Pagar Study, visual acuity and mortality, 802
Choroidal nevi
in adult Chinese *(Letter)*, 1102
clinical spectrum of, 546
Choroideremia
lines of Blaschko *(Letter)*, 1855
mosaic retinal dysfunction in carriers of, 723
Clinical studies. *See also* Randomized, controlled trials
bias and sponsored research *(Letter)*, 412
factors associated with IOP before and during 9 years of treatment in Collaborative Initial Glaucoma Treatment Study, 927
intravitreal ranibizumab for retinal capillary hemangioblastoma in von Hippel-Lindau disease, 1957
statistical tools: hypothesis testing, confidence intervals and power of clinical studies *(Editorial)*, 423
three-year results of Artisan/Verisyse phakic IOL implantation, 464
CMV. *See* Cytomegalovirus
Collaborative Ocular Melanoma Study, baseline echographic characteristics of tumors in, 1390
Combat ocular trauma visual outcomes during Operations Iraqi and Enduring Freedom, 2235
Competency-based education in ophthalmology, national program director survey of shift to, 1426
Complement system
AMD and complement activation–related diseases, 1904
complement factor H Y402H variant in AMD
CFH and *LOC387715/ARMS2* genotypes and treatment with antioxidants and zinc for AMD, 1019
peripheral reticular pigmentary change and, 520
inflammation, complement factor H, and AMD, 1742
Complementary and alternative medicine for glaucoma, 435
Complications. *See also* Adverse drug effects
cataract surgery complication rates *(Letter)*, 1432
corneal ectasia after excimer laser keratorefractive surgery, 2181
of Descemet's stripping endothelial keratoplasty (DSEK), 1517
diffuse lamellar keratitis *(Letter)*, 1848
ectasia after refractive surgery *(Letter)*, 1849
incidence of endophthalmitis after 20- and 25-gauge vitrectomy, 2215
IOP elevation within 24 hours in patients with glaucoma or exfoliation syndrome, 104
management of dislocated IOLs, 1699
optimizing outcomes *(Editorial)*, 1
premature silicone stent loss after dacryocystorhinostomy, 1241
rainbow glare as optical side effect of IntraLASIK, 1187
of retinal endovascular lysis *(Letter)*, 216
risk assessment for ectasia after corneal refractive surgery, 37
after scleral fixation of posterior chamber IOLs in children, 67
techniques to monitor for endophthalmitis and other cataract surgery complications, 3
traumatic graft dehiscence after PK, 276
vitreous cavity hemorrhage after diabetic vitrectomy, 525
Complications of Age-Related Macular Degeneration Prevention Trial
characteristics of choroidal neovascularization in, 1468
night vision symptoms and progression of AMD, 1876
risk factors for choroidal neovascularization and geographic atrophy in, 1474
Computed tomography (CT)
CT angiography in isolated third nerve palsy, 1411
CT underestimation of soft tissue entrapment in pediatric orbital floor fractures, 1620
temporal fossa decompression for disfiguring thyroid-related orbitopathy, 1613
Computers, dry eye disease among Japanese visual display terminal users, 1982
Conflicts of interest, bias and sponsored research *(Letter)*, 412
Confocal microscopy
in atopic keratoconjunctivitis, 2004
filtering blebs and aqueous pathway, 1154
Confocal scanning laser ophthalmoscopy, patient opinions of clinical tests used in glaucoma management, 2127
Conjunctiva
bacterial conjunctivitis in South Florida, 51
cyclosporine for conjunctival sarcoidosis *(Letter)*, 222
lens capsule and conjunctival tissues in clinically unilateral pseudoexfoliation syndrome, 614
one-day vs. one-hour application of topical gatifloxacin in eliminating conjunctival bacterial flora, 2013
pigmented squamous cell carcinoma in situ of, 1673
primary acquired melanosis and risks for progression to melanoma, 511
prospective study of pterygium extended removal followed by extended conjunctival transplantation, 1663
topical interferon alfa-2b treatment of conjunctival and corneal intraepithelial neoplasia, 1291
Contact lenses, microbial keratitis associated with
incidence in Australia, 1655
risk factors for, 1647
Continuing medical education (CME), supplementary intracameral lidocaine for phacoemulsification under topical anesthesia, 455
Cornea
amantadine-associated corneal edema, 1540
central corneal thickness measurement with slip-lamp OCT vs. Visante OCT, 796
diabetes, hyperglycemia, and central corneal thickness, 964
influence of corneal properties on rebound tonometry, 80
OCT of corneal opacities *(Letter)*, 589
posterior surface *(Letter)*, 588
Corneal ectasia
after excimer laser keratorefractive surgery, 2181
after refractive surgery
(Letter), 1849
risk assessment for, 37

Corneal endothelial cells
CMV as etiologic factor in corneal endotheliitis, 292
loss after Artisan phakic IOL implantation, 608
loss after corneal transplantation, donor age and, 627
Corneal hysteresis and ocular pulse amplitude, heritability of, 1545
Corneal magnification *(Letter)*, 588
Corneal transplantation
donor age and corneal endothelial cell loss after, 627
donor age and outcome of, 620
same-sizing vs. oversizing donor trephines in keratoconus, 268
Corticosteroids
adjunctive triamcinolone acetonide in silicone-filled eyes for proliferative vitreoretinopathy, 1938
intralesional, for astigmatism induced by periocular capillary hemangioma, 390
intraocular concentration of triamcinolone acetonide after intravitreal injection (rabbit), 1372
intravitreal triamcinolone acetonide vs. focal/grid photocoagulation for diabetic macular edema, 1447
intravitreal triamcinolone and blood glucose *(Letter)*, 916
intravitreal triamcinolone *(Letter)*, 1436
ptosis after sub–Tenon's capsule triamcinolone *(Letter)*, 410
Cost-utility analysis. *See also* Economic issues
impact of anchor point on utilities for 5 common diseases, 898
of ranibizumab for subfoveal neovascular macular degeneration, 1039
for treatment of AMD, 2192
Craniofacial clefts, Tessier number 10 clefts, 2290
CRVO. *See* Central retinal vein occlusion
Cryotherapy for pterygia *(Letter)*, 2314
Crystalline macular dystrophy in Sjögren–Larsson syndrome, 870
CSF. *See* Cerebrospinal fluid pressure
CT. *See* Computed tomography
Cyclophosphamide, for ocular mucous membrane pemphigoid, 2146
Cyclosporine, for conjunctival sarcoidosis *(Letter)*, 222
Cysticercosis of optic nerve *(Letter)*, 2094
Cystoid macular edema, in retinal vein occlusion, 3D OCT imaging, 355
Cytologic analysis of vitreous specimens, 1944
Cytomegalovirus (CMV)
as etiologic factor in corneal endotheliitis, 292
retinitis after hematopoietic stem cell transplantation with alemtuzumab, 1766

D

Dacryocystorhinostomy, premature silicone stent loss after, 1241
Dengue fever, ocular complications *(Letter)*, 1100 (erratum, 1524)
Dermis fat grafting, for treatment of lower eyelid malposition, 744
Descemet's stripping endothelial keratoplasty (DSEK)
automated, precut tissue in, 497
complications of, 1517
endothelial cell loss after, 488, 857
in eyes with double glaucoma tubes *(Letter)*, 1435
Diabetes mellitus
diabetes, hyperglycemia, and central corneal thickness, 964
influence on thickness, shape, and equivalent refractive index of lens, 1679
internal lens structure in diabetes types 1 and 2, 2017
Los Angeles Latino Eye Study, type 2 diabetes mellitus and risk of open-angle glaucoma, 227
macular edema in
analysis methods in OCT studies of, 1366
intravitreal triamcinolone acetonide vs. focal/grid photocoagulation for, 1447
macular thickness and diabetic retinopathy severity, 533
a new look at an old treatment for *(Editorial)*, 1445
OCT in *(Letter)*, 417
surrogate marker for visual function *(Letter)*, 416
metabolic syndrome components and risk of cataract extraction in women, 1687
NAION in patients with, 1818
Singapore Malay Eye Study, prevalence and risk factors for diabetic retinopathy, 1869
soluble VEGF receptor-1 in vitreous in proliferative diabetic retinopathy, 1916
vitrectomy and lens status *(Letter)*, 415
vitreous cavity hemorrhage after diabetic vitrectomy, 525
vitreous levels of reactive oxygen species in proliferative diabetic retinopathy, 734
Wisconsin Epidemiologic Study of Diabetic Retinopathy
25-year progression of retinopathy in type 1 diabetes, 1859 *(Editorial)*, 1857
Diet
antioxidants and long-term incidence of AMD, 334
multivitamin supplementation for age-related lens opacities, 599
multivitamin supplements and cataract prevention *(Editorial)*, 597
supplements and age-related eye conditions, 1203
vitamin E and age-related cataract in randomized trial of women, 822
Diplopia, blepharoptosis, ophthalmoplegia and statin use, 2282
Disc hemorrhage in primary angle-closure glaucoma, 1328
Doctor–patient communication, health-related beliefs, and adherence in glaucoma, 1320
Dorzolamide
meta-analysis of 24-hour IOP studies evaluating efficacy of glaucoma medications, 1117
24-hour IOP-lowering effects of latanoprost vs. dorzolamide/timolol, 99
Drusen, ultrastructure imaging with spectral domain OCT in AMD, 1883
Dry eye disease, among Japanese visual display terminal users, 1982
DSEK. *See* Descemet's stripping endothelial keratoplasty

E

Early Manifest Glaucoma Trial
disc hemorrhages and treatment in, 2044
visual field progression criteria of 3 major glaucoma trials, 1557
Early Treatment Diabetic Retinopathy Study chart, visual acuity in macular degeneration patients measured with Snellen chart and, 319
East Timor, eye health in *(Letter)*, 1263
Economic issues. *See also* Cost-utility analysis
charges for cataract surgery *(Letter)*, 210
cost-effectiveness *(Letter)*, 1852
cost-effectiveness of small-incision cataract surgery *(Letter)*, 211
cost-effectiveness of treating ocular hypertension, 94 (erratum, 1524) *(Letter)*, 1433
direct costs of blindness experienced by patients enrolled in managed care, 11
eye-related Medicare costs for patients with AMD 1995–1999, 18
gender differences in ophthalmologists' income *(Letter)*, 411
glass ceiling? *(Letter)*, 595
health care charges for patients with ocular hypertension or glaucoma, 633
Editorials
American Academy of Ophthalmology adopts SNOMED CT as its official clinical terminology, 225
improving patient-centered care, 1645
increased transparency: making the journal better for readers and for authors, 1443
low ICP: tipping point in understanding of primary OAG?, 761
mandating comprehensive eye examinations for children, 1271
multivitamin supplements and cataract prevention, 597
a new look at an old treatment for diabetic macular edema, 1445

optimizing outcomes, 1
PPPs–twenty years and counting, 2125
progress toward personalized medicine for AMD, 925
statistical tools: hypothesis testing, confidence intervals and power of clinical studies, 423
trab vs. tube, a 15-year retrospective, 1107
Wisconsin Epidemiologic Study of Diabetic Retinopathy, 1857
Electronic health records
American Academy of Ophthalmology adopts SNOMED CT as its official clinical terminology *(Editorial)*, 225
ophthalmologists' adoption and perceptions of, 1591
Electroretinography (ERG)
mosaic retinal dysfunction in choroideremia carriers, 723
reproducibility of pattern ERG in glaucoma, 957
Endophthalmitis
after cataract surgery (1996–2005), 473
after cataract surgery *(Letter)*, 413
exogenous fungal, 1501
incidence after 20- and 25-gauge vitrectomy, 2215
techniques to monitor for cataract surgery complications, 3
Endothelial cells, corneal
CMV as etiologic factor in corneal endotheliitis, 292
loss after Artisan phakic IOL implantation, 608
loss after corneal transplantation, donor age and, 627
Endothelial keratoplasty, 1179
Descemet's stripping (DSEK)
automated, precut tissue in, 497
complications of, 1517
endothelial cell loss after, 488, 857
in eyes with double glaucoma tubes *(Letter)*, 1435
eye bank–prepared tissue for, 279
(Letter), 420
Endothelin-1 in ischemic optic neuropathy *(Letter)*, 1262
Enophthalmos, intraorbital hyaluronic acid for *(Letter)*, 1101
Entropion, involutional, fornix fat prolapse as sign for, 1608
Epidemiology
acute-onset endophthalmitis after cataract surgery (1996–2005), 473
bacterial conjunctivitis in South Florida, 51
Baltimore Pediatric Eye Disease Study
low concordance of fixation preference with visual acuity in preschool children, 1796
prevalence of decreased vision in preschool children, 1786
Barbados Eye Studies
pterygium incidence and risk factors in, 2153
risk factors for incident open-angle glaucoma, 85
Beaver Dam Eye Study
age–period–cohort effect on incidence of AMD, 1460
incidence of age-related cataract over 15-year interval, 477
supplements and age-related eye conditions, 1203
Blue Mountains Eye Study
dietary antioxidants and long-term incidence of AMD, 334
retinal vessel caliber and incidence of age-related cataract, 1693
ten-year incidence of age-related cataract and cataract surgery in Australian population, 808
British Congenital Cataract Study, glaucoma after surgery for congenital cataract, 1013
central serous chorioretinopathy in Olmsted County, MN, 1980–2002, 169
Chennai Glaucoma Study
prevalence of open-angle glaucoma in South India, 648
prevalence of primary angle-closure glaucoma in South India, 655
contact lens–related microbial keratitis
incidence in Australia, 1655
risk factors for, 1647
eye health in East Timor *(Letter)*, 1263
Funagata Study, prevalence and risk factors for AMD in adult Japanese population, 1376
Greenland Inuit Eye Study, prevalence of ARM and AMD, 700
Handan Eye Study, low vision and blindness in rural Chinese adults, 1965
hypothyroidism and open-angle glaucoma in elderly population, 1581
LOC387715 polymorphism, inflammatory markers, smoking, and AMD, 693
longitudinal rates of postoperative adverse outcomes after glaucoma surgery, 1109
Los Angeles Latino Eye Study
impact of visual field loss on quality of life in glaucoma, 941
sociodemographic, family history, and lifestyle risk factors for open-angle glaucoma and ocular hypertension, 639
type 2 diabetes mellitus and risk of open-angle glaucoma, 227
visual acuity after cataract extraction in adult Latinos, 815
Meiktila Eye Study, refractive error in rural Myanmar, 26
metabolic syndrome components and risk of cataract extraction in women, 1687
Multi-Ethnic Pediatric Eye Disease Study
amblyopia and strabismus in African American and Hispanic children, 1229
testability of Retinomax Autorefractor and IOLMaster in preschool children, 1422
Multi-Ethnic Study of Atherosclerosis, inflammation, complement factor H, and AMD, 1742
prevalence of hyperopia in 6- and 12-year-olds, 678
refractive error in Myanmar *(Letter)*, 1642
Rotterdam Study
oxygen saturation, cerebral blood flow, and retinal vessel diameters, 887
VEGF gene polymorphisms and AMD risk, 1899
Salisbury Eye Evaluation, glaucoma and quality of life, 233
season of birth, natural light, and myopia, 686
severe eye injuries in war in Iraq, 377
Singapore Corneal Transplant Study, PK in Asian eyes, 975
Singapore Malay Eye Study
diabetes, hyperglycemia, and central corneal thickness, 964
prevalence and risk factors for diabetic retinopathy, 1869
prevalence and risk factors for refractive errors in, 1713
prevalence of AMD in, 1735
vision impairment, ocular conditions, and vision-specific function, 1973
Sydney Myopia Study, outdoor activity and myopia prevalence in children, 1279
Tajimi Study, refractive errors in elderly Japanese population, 363
Tanjong Pagar Study, visual acuity and mortality in Chinese population, 802
Wisconsin Epidemiologic Study of Diabetic Retinopathy
25-year progression of retinopathy in type 1 diabetes, 1859 *(Editorial)*, 1857
Epiretinal membrane, binocular vision after surgery to remove, 1930
ERG. *See* Electroretinography
Errata, 472, 1524, 1922
Esotropia, instability of ocular alignment in children with, 2266
Ethical issues, bias and sponsored research *(Letter)*, 412
Exfoliation syndrome, IOP elevation within 24 hours after cataract surgery in patients with glaucoma or, 104
Exotropia, intermittent, variability of control in, 371
Extraocular muscles
functional anatomy of inferior rectus muscle in superior oblique muscle palsy, 2079
orbicularis muscle advancement flap combined with free posterior and anterior lamellar grafts, 189
Eye bank–prepared endothelial keratoplasty tissue, 279

Eye drops
autologous serum eyedrops in aniridic keratopathy, 262
compliance in religious fasting *(Letter)*, 1440
Eyelid
diplopia, blepharoptosis, ophthalmoplegia and statin use, 2282
eyelid retraction, lid lag, lagophthalmos, and von Graefe's sign in Graves' ophthalmopathy, 1083
fornix fat prolapse as sign for involutional entropion, 1608
lid reconstruction *(Letter)*, 1643
Merkel cell carcinoma of, 195
ptosis after sub–Tenon's capsule triamcinolone *(Letter)*, 410
reconstruction with orbicularis muscle advancement flap combined with free posterior and anterior lamellar grafts, 189
treatment of lower eyelid malposition with dermis fat grafting, 744

F

Fluorescein angiography, one-year results of PDT in AMD and polypoidal choroidal vasculopathy in Japanese patients, 141
Foreign bodies, severe eye injuries in war in Iraq, 377
Fornix fat prolapse as sign for involutional entropion, 1608
Foveal depression and albinism *(Letter)*, 756
Frequency doubling technology perimetry, patient opinions of clinical tests used in glaucoma management, 2127
Funagata Study, prevalence and risk factors for AMD in adult Japanese population, 1376
Fundus photography
geographic atrophy in AMD, 1026
subthreshold diode micropulse photocoagulation for central serous chorioretinopathy, 2229
Fungal keratitis
hyphal growth patterns and recurrence of, after lamellar keratoplasty, 983
treatment failure after lamellar keratoplasty for, 33

G

Gastrointestinal stromal tumor (GIST), ulcerative keratitis in patients treated with perifosine, 483
Gatifloxacin, one-day vs. one-hour topical application in eliminating conjunctival bacterial flora, 2013
Gender differences in ophthalmologists' income
glass ceiling? *(Letter)*, 595
(Letter), 411
Genetics
alleles in HtrA serine peptidase 1 gene and risk of neovascular AMD, 1209
of AMD *(Letter)*, 916
bilateral synergistic convergence associated with homozygous *ROB03* mutation, 2262
CFH and *LOC387715/ARMS2* genotypes and treatment with antioxidants and zinc for AMD, 1019
complement factor H Y402H variant in AMD, peripheral reticular pigmentary change and, 520
heritability of corneal hysteresis and ocular pulse amplitude, 1545
HtrA1 promoter polymorphism, smoking, and AMD, 1891
LOC387715 polymorphism, inflammatory markers, smoking, and AMD, 693
of myopia, 1053
of myopic choroidal neovascularization *(Letter)*, 1632
ophthalmic examination and carrier status for Norrie disease gene mutation, 730
progress toward personalized medicine for AMD *(Editorial)*, 925
Rotterdam Study, VEGF gene polymorphisms and AMD risk, 1899
Geographic atrophy
development in AMD, 1026
low luminance function and, in AMD, 1480
risk factors for, in AMD, 1474
Geriatric population
alleles in HtrA serine peptidase 1 gene and risk of neovascular AMD, 1209
anterior chamber depth in elderly Chinese, 1286
autofluorescence imaging in AMD with choroidal neovascularization, 342
Beaver Dam Eye Study, incidence of age-related cataract over 15-year interval, 477
carotenoids and antioxidants in ARM, 324
dietary antioxidants and long-term incidence of AMD, 334
donor age and corneal transplantation outcome, 620
eye-related Medicare costs for patients with AMD 1995–1999, 18
hypothyroidism and open-angle glaucoma in, 1581
LOC387715 polymorphism, inflammatory markers, smoking, and AMD, 693
macular carotenoid levels in Japanese ARM patients, 147
more intense vs. standard early verteporfin treatment of neovascular AMD, 134
multivitamin supplementation for age-related lens opacities, 599
natural history and prognosis for neovascular AMD, 116 (erratum, 1524)
OCT after pegaptanib or bevacizumab in neovascular AMD, 347
one-year results of PDT in AMD and polypoidal choroidal vasculopathy in Japanese patients, 141
peripheral reticular pigmentary change and complement factor H Y402H variant in AMD, 520
prevalence and risk factors for AMD in adult Japanese population, 1376
prevalence of ARM and AMD among Inuit in Greenland, 700
refractive errors in elderly Japanese population, 363
relationship of 10-year change in refraction to nuclear cataract and axial length, 1273
supplements and age-related eye conditions, 1203
GIST. *See* Gastrointestinal stromal tumor
Glass ceiling *(Letter)*, 595
Glaucoma. *See also* Ocular hypertension
aqueous shunts in *(Ophthalmic Technology Assessment)*, 1089
assessment of glaucoma imaging technology *(Letter)*, 1265
combining RNFL parameters to optimize OCT diagnosis of, 1352
comparison of parameters from HRT versions 2 and 3, 673
CSF pressure and *(Letter)*, 2316, 2317
disc hemorrhages and treatment in Early Manifest Glaucoma Trial, 2044
doctor–patient communication, health-related beliefs, and adherence in, 1320
early phacoemulsification vs. peripheral iridotomy to prevent IOP rise after acute primary angle closure, 1134
effect of nilvadipine on visual field and ocular circulation in, 2049
effect of nilvadipine on visual field and ocular circulation in glaucoma, 2049
end-stage, survival of central vision in, 1162
high-speed ultrahigh-resolution OCT for visualization of retinal damage in, 782
HRT 3 diagnostic accuracy across disc sizes and glaucoma stages, 1358
HRT 3 in discriminating between normal and glaucoma-damaged eyes, 775
hypothyroidism and open-angle glaucoma in elderly population, 1581
impact of visual field loss on quality of life in, 941
influence of corneal properties on rebound tonometry, 80
Internet-based review of complementary and alternative medicine for, 435
intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma, 1571

IOP elevation within 24 hours after cataract surgery in patients with exfoliation syndrome or, 104
IOP fluctuation and visual field progression, 1123
IOP increase with water drinking test in, 1566
IOP-lowering efficacy of brinzolamide/timolol, 1728
long-term IOP fluctuations and risk of conversion from ocular hypertension to, 934
mapping of macular substructures with OCT for diagnosis of, 949
meta-analysis of 24-hour IOP studies evaluating efficacy of glaucoma medications, 1117
more may be less *(Letter)*, 1265
mortality and *(Letter)*, 213
narrow angles *(Letter)*, 214
normal-tension, *(Letter)*, 590
ocular surface of treated patients expresses CCR5 and CCR4, 109
open-angle (OAG)
CSF pressure in primary OAG, 763
early, diagnostic capability of scanning laser polarimetry in, 1167
factors associated with IOP before and during 9 years of treatment in Collaborative Initial Glaucoma Treatment Study, 927
health care charges for patients with, 633
and hypothyroidism in elderly population, 1581
low ICP: tipping point in understanding of primary OAG? *(Editorial)*, 761
ocular hypertension and predictive models for, 2030
optic nerve head topography and visual field in angle-closure glaucoma and, 239
peripheral vascular endothelial dysfunction and, 1173
prevalence in South India, 648
rates of glaucoma medication usage in, 1315
risk factors in Barbados Eye Studies, 85
sociodemographic, family history, and lifestyle risk factors for, 639
type 2 diabetes mellitus and risk of, 227
patient opinions of clinical tests used in management of, 2127
primary angle-closure
disc hemorrhage in, 1328
prevalence in South India, 655
scanning laser polarimetry with variable corneal compensation in, 1334
ultrasound biomicroscopy study of plateau iris in, 430
utility of symptoms in identification of, 2024
quality of life and, 233
reproducibility of pattern ERG in, 957
reproducibility of peripapillary RNFL thickness measurements with Stratus OCT in, 661
retinal blood flow response to posture change in, 246
RNFL vs. optic disc imaging for diagnosis of, 1340
screening for narrow angles in Singapore population, 1720
after surgery for congenital cataract, 1013
topical β-blockers and mortality, 2037
24-hour IOP-lowering effects of latanoprost vs. dorzolamide/timolol, 99
visual field changes after transient IOP elevation, 667
visual field progression criteria of 3 major glaucoma trials, 1557
Glaucoma drainage devices
Descemet's stripping endothelial keratoplasty in eyes with double glaucoma tubes *(Letter)*, 1435
efficacy of Ahmed S2 Glaucoma Valve vs. Baerveldt 250-mm^2 Glaucoma Implant, 1141
longitudinal rates of postoperative adverse outcomes after glaucoma surgery, 1109
trab vs. tube, a 15-year retrospective *(Editorial)*, 1107
Glaucoma surgery
anesthesia for phacotrabeculectomy *(Letter)*, 752
comparison of 1-site and 2-site phacotrabeculectomy, 447, 1130
efficacy of Ahmed S2 Glaucoma Valve vs. Baerveldt 250-mm^2 Glaucoma Implant, 1141
filtering blebs and aqueous pathway, 1154
longitudinal rates of postoperative adverse outcomes, 1109
needling revision of trabeculectomy, 1148
phacoemulsification vs. combined phacotrabeculectomy in chronic angle closure glaucoma with cataract, 2167
subconjunctival bevacizumab as adjunct to trabeculectomy, 2141
trab vs. tube, a 15-year retrospective *(Editorial)*, 1107
Globe injuries
perforating, during Operation Iraqi Freedom, 2087
predicting vision survival after open injury, 202
Goldmann applanation tonometry, patient opinions of clinical tests used in glaucoma management, 2127
Gonioscopy, vs. anterior segment OCT in detecting angle closure in different quadrants of anterior chamber angle, 769
Graves' ophthalmopathy
eyelid retraction, lid lag, lagophthalmos, and von Graefe's sign in, 1083
orbital radiation for *(Ophthalmic Technology Assessment)*, 398
Greenland Inuit Eye Study, prevalence of ARM and AMD, 700

H

Hamartoma of retina and RPE, 2246
Handan Eye Study, low vision and blindness in rural Chinese adults, 1965
Hearing loss, sensorineural, in pseudoexfoliation syndrome, 425
Heidelberg Retina Tomograph (HRT)
comparison of parameters from HRT versions 2 and 3, 673
HRT 3 diagnostic accuracy across disc sizes and glaucoma stages, 1358
HRT 3 in discriminating between normal and glaucoma-damaged eyes, 775
optic nerve head topography and visual field in open-angle and angle-closure glaucoma, 239
patient opinions of clinical tests used in glaucoma management, 2127
visual function–optic nerve structure correlation, 440
Hemangioblastoma
of optic nerve *(Letter)*, 2094
in von Hippel–Lindau disease
retinal capillary, 181
intravitreal ranibizumab for, 1957
retrobulbar, 1382
Hemangioma, periocular capillary
astigmatism and *(Letter)*, 1854
intralesional corticosteroids for astigmatism induced by, 390
Hematopoietic stem cell transplantation, CMV retinitis after transplantation with alemtuzumab, 1766
Histopathology
anterior uveitis in juvenile idiopathic arthritis, 1833
bicanalicular obstruction in lichen planus, 386
conjunctival primary acquired melanosis and risks for progression to melanoma, 511
corneal ectasia after excimer laser keratorefractive surgery, 2181
hyphal growth patterns and recurrence of fungal keratitis after lamellar keratoplasty, 983
incontinentia pigmenti retinopathy, 893
Merkel cell carcinoma of eyelid, 195
myxofibrosarcoma of orbit, 1237
new classification of IOL calcification, 73
OCT and histopathology of sutureless vitrectomy wounds, 2221
pigmented squamous cell carcinoma in situ of conjunctiva, 1673
retrobulbar hemangioblastomas in von Hippel–Lindau disease, 1382
routes of extraocular extension of uveal melanoma, 1778
Histoplasmosis, surgical removal of peripapillary choroidal

neovascularization in presumed ocular histoplasmosis syndrome, 540
Hookworm infestation *(Letter)*, 224
HRT. *See* Heidelberg Retina Tomograph
HtrA1 promoter polymorphism, smoking, and AMD, 1891
HtrA serine peptidase 1 gene and risk of neovascular AMD, 1209
Human immunodeficiency virus–induced uveitis, 2062
Hurricane Katrina, Tulane University after *(Letter)*, 921
Hyaluronic acid, intraorbital, for enophthalmos *(Letter)*, 1101
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors, diplopia, blepharoptosis, ophthalmoplegia and use of, 2282
Hydroxyapatite orbital implants
exposure rate over 15 years, 566
(Letter), 2096, 2320
Hyperglycemia. *See also* Diabetes mellitus
diabetes, hyperglycemia, and central corneal thickness, 964
intravitreal triamcinolone and blood glucose *(Letter)*, 916
Hyperopia
evaluation of internal refraction with optical path difference scan, 57
five-year follow-up of 399 Artisan–Verisyse phakic IOLs for, 1002
prevalence and risk factors in Singapore Malay Eye Study, 1713
prevalence in 6- and 12-year-olds, 678
Hypertension
cardiovascular disease, choroidal neovascularization, and, 1046
metabolic syndrome components and risk of cataract extraction in women, 1687
Hypothyroidism and open-angle glaucoma in elderly population, 1581

I

ICP. *See* Intracranial pressure
Idiopathic intracranial hypertension, recurrent *(Letter)*, 221
Immunosuppressive therapy, for ocular mucous membrane pemphigoid, 253, 2146
Incontinentia pigmenti retinopathy, 893
Indocyanine green angiography, one-year results of PDT in AMD and polypoidal choroidal vasculopathy in Japanese patients, 141
Infantile orbital cellulitis *(Letter)*, 594
Infection
acute-onset endophthalmitis after cataract surgery (1996–2005), 473
bacterial conjunctivitis in South Florida, 51
CMV as etiologic factor in corneal endotheliitis, 292
CMV retinitis after hematopoietic stem cell transplantation with alemtuzumab, 1766
contact lens–related microbial keratitis
incidence in Australia, 1655
risk factors for, 1647
exogenous fungal endophthalmitis, 1501
human immunodeficiency virus–induced uveitis, 2062
hyphal growth patterns and recurrence of fungal keratitis after lamellar keratoplasty, 983
incidence of endophthalmitis after 20- and 25-gauge vitrectomy, 2215
moxifloxacin for bacterial keratitis *(Letter)*, 1103
new eye lesions in treated congenital toxoplasmosis, 553
ocular complications of dengue fever *(Letter)*, 1100 (erratum, 1524)
ocular manifestations of chikungunya, 287
one-day vs. one-hour application of topical gatifloxacin in eliminating conjunctival bacterial flora, 2013
optic nerve cysticercosis *(Letter)*, 2094
surgical removal of peripapillary choroidal neovascularization in presumed ocular histoplasmosis syndrome, 540
treatment failure after lamellar keratoplasty for fungal keratitis, 33
Inferior rectus muscle, functional anatomy in superior oblique muscle palsy, 2079
Inflammation. *See also specific inflammatory disorders*
antimetabolite drugs for noninfectious ocular inflammation, 1826
complement factor H, AMD and, 1742
after intravitreous bevacizumab injections for neovascular AMD, 1911
LOC387715 polymorphism, inflammatory markers, smoking, and AMD, 693
mycophenolate mofetil after methotrexate for scleritis and uveitis, 1416
ocular surface of treated glaucoma patients expresses CCR5 and CCR4, 109
tacrolimus ointment for refractory ocular surface inflammatory diseases, 988
Interferon alfa-2b, topical
for conjunctival and corneal intraepithelial neoplasia, 1291
vs. surgical excision for primary ocular surface squamous neoplasia, 1297
Intermittent exotropia, variability of control in, 371
Internet-based review, of complementary and alternative medicine for glaucoma, 435
Intracranial pressure (ICP)
decreased CSF in primary OAG, 763
low ICP: tipping point in understanding of primary OAG? *(Editorial)*, 761
recurrent idiopathic intracranial hypertension *(Letter)*, 221
IntraLASIK, rainbow glare as optical side effect of, 1187
Intraocular lens (IOL)
accommodating IOLs *(Letter)*, 1850
Artisan phakic IOL *(Letter)*, 753
comparing ICU accommodative, multifocal, and monofocal IOLs, 993
depth of focus *(Letter)*, 1438
effect of AcrySof vs. silicone or polymethyl methacrylate IOL on posterior capsule opacification, 830
endothelial cell changes after Artisan phakic IOL implantation, 608
five-year follow-up of 399 Artisan–Verisyse phakic IOLs, 1002
implantation of black diaphragm IOL in aniridia, 1705
management of dislocated IOLs, 1699
new classification of IOL calcification, 73
one-year outcomes with new-generation multifocal IOLs, 1508
optic edge design as long-term factor for posterior capsular opacification, 1308
phakic IOLs in children *(Letter)*, 592
refraction after IOL exchange *(Letter)*, 754
scleral fixation of posterior chamber IOLs in children, 67
spherical aberration and depth of focus *(Letter)*, 1641
three-year results of Artisan/Verisyse phakic IOL implantation, 464
Intraocular pressure (IOP)
factors associated with IOP before and during 9 years of treatment in Collaborative Initial Glaucoma Treatment Study, 927
increase with water drinking test in glaucoma patients, 1566
influence of corneal properties on rebound tonometry, 80
IOP elevation within 24 hours after cataract surgery in patients with glaucoma or exfoliation syndrome, 104
IOP fluctuation and visual field progression, 1123
long-term IOP fluctuations and risk of conversion from ocular hypertension to glaucoma, 934
visual field changes after transient IOP elevation, 667
Intraocular pressure (IOP) control
aqueous shunts in glaucoma *(Ophthalmic Technology Assessment)*, 1089
comparison of 1-site and 2-site phacotrabeculectomy, 447, 1130
cost-effectiveness of treating ocular hypertension, 94 (erratum, 1524) *(Letter)*, 1433
early phacoemulsification vs. peripheral iridotomy to prevent IOP rise after acute primary angle closure, 1134
efficacy of Ahmed S2 Glaucoma Valve vs. Baerveldt 250-mm^2 Glaucoma Implant, 1141
IOP-lowering efficacy of brinzolamide/timolol, 1728
meta-analysis of 24-hour IOP studies evaluating efficacy of glaucoma medications, 1117

needling revision of trabeculectomy, 1148
transscleral cyclodiode laser photocoagulation in aqueous misdirection syndrome, 2058
24-hour IOP-lowering effects of latanoprost vs. dorzolamide/timolol, 99
Intraocular telescope *(Letter)*, 921, 1437
Intravenous immunoglobulins, for mucous membrane pemphigoid *(Letter)*, 752
Involutional entropion, fornix fat prolapse as sign for, 1608
IOL. *See* Intraocular lens
IOP. *See* Intraocular pressure
Iraq war
combat ocular trauma visual outcomes during, 2235
perforating globe injuries during, 2087
severe eye injuries in, 377
Iris
cataract and iris atrophy during treatment of *Acanthamoeba* keratitis, 866
intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma, 1571
morphology *(Letter)*, 418
ultrasound biomicroscopy study of plateau iris in primary angle closure subjects, 430
Ischemic Optic Neuropathy Decompression Trial, visual fields at follow-up in, 1809

J

Japanese population
acute retinal necrosis in *(Letter)*, 1632
dry eye disease among Japanese visual display terminal users, 1982
guidelines for PDT in Japan *(Letter)*, 585
macular carotenoid levels in ARM patients, 147
one-year results of PDT in AMD and polypoidal choroidal vasculopathy in, 141
prevalence and risk factors for AMD in adults, 1376
refractive errors in elderly persons, 363
Joubert syndrome, 2286
Juvenile idiopathic arthritis, anterior uveitis in, 1833
Juxtafoveal telangiectasias *(Editorial)*, 1636

K

Keratitis
Acanthamoeba
cataract and iris atrophy during treatment of, 866
prognostic factors affecting visual outcome in, 1998
contact lens–related microbial
incidence in Australia, 1655
risk factors for, 1647
diffuse lamellar *(Letter)*, 1848
fungal
hyphal growth patterns and recurrence of, after lamellar keratoplasty, 983
treatment failure after lamellar keratoplasty for, 33
moxifloxacin for *(Letter)*, 1103
ulcerative, in GIST patients treated with perifosine, 483
Keratoconjunctivitis, atopic, corneal in vivo confocal scanning laser microscopy in, 2004
Keratoconus
detection by posterior corneal elevation with Pentacam, 1534
diagnosis with OCT pachymetry mapping, 2159
keratocyte density in, 845
postkeratoplasty atopic sclerokeratitis in patients with, 851
same-sizing vs. oversizing donor trephines in, 268
Keratoplasty
Descemet's stripping endothelial (DSEK)
automated, precut tissue in, 497
complications of, 1517
endothelial cell loss after, 488, 857
in eyes with double glaucoma tubes *(Letter)*, 1435
endothelial, 1179
eye bank–prepared tissue for, 279
(Letter), 420
lamellar
deep anterior *(Letter)*, 1847
femtosecond laser–assisted sutureless anterior, 1303
for fungal keratitis, treatment failure after, 33
hyphal growth patterns and recurrence of fungal keratitis after, 983
penetrating (PK)
in Asian eyes, 975
comparison of posterior lamellar keratoplasty techniques to, 1525
same-sizing vs. oversizing donor trephines in keratoconic patients undergoing, 268
traumatic graft dehiscence after, 276
postkeratoplasty atopic sclerokeratitis in keratoconus patients, 851
Keratoprosthesis surgery, for end-stage corneal blindness in Asian eyes, 503

L

Lacrimal system
bicanalicular obstruction in lichen planus, 386
double silicone tube intubation for partial obstruction of, 383
lacrimal surgery *(Letter)*, 759
nasolacrimal duct probing in children younger than 4 years, 577
premature silicone stent loss after dacryocystorhinostomy, 1241
Lagophthalmos, eyelid retraction, lid lag, and von Graefe's sign in Graves' ophthalmopathy, 1083
Lamellar keratoplasty
comparison of posterior lamellar keratoplasty techniques to PK, 1525
deep anterior *(Letter)*, 1847
femtosecond laser–assisted sutureless anterior, 1303
for fungal keratitis, treatment failure after, 33
hyphal growth patterns and recurrence of fungal keratitis after, 983
Laser in situ keratomileusis (LASIK)
corneal magnification and *(Letter)*, 588
Epi-LASIK vs. off-flap Epi-LASIK for low and moderate myopia, 2174
five-year outcome for myopia, 839
monovision in, 1196
posterior corneal surface after *(Letter)*, 588
rainbow glare as optical side effect of IntraLASIK, 1187
risk assessment for ectasia after corneal refractive surgery, 37
wavefront-guided LASIK for correction of primary myopia and astigmatism *(Ophthalmic Technology Assessment)*, 1249
Laser technology
corneal ectasia after excimer laser keratorefractive surgery, 2181
diagnostic capability of scanning laser polarimetry in early open-angle glaucoma, 1167
femtosecond laser–assisted sutureless anterior lamellar keratoplasty, 1303
intravitreal triamcinolone acetonide vs. focal/grid photocoagulation for diabetic macular edema, 1447
laser scanning in vivo confocal analysis of keratocyte density in keratoconus, 845
a new look at an old treatment for diabetic macular edema *(Editorial)*, 1445
subthreshold diode micropulse photocoagulation for central serous chorioretinopathy, 2229
subthreshold laser irradiation *(Letter)*, 216
transscleral cyclodiode laser photocoagulation in aqueous misdirection syndrome, 2058

LASIK. *See* Laser in situ keratomileusis
Latanoprost
  mechanism of action, 790
  meta-analysis of 24-hour IOP studies evaluating efficacy of glaucoma medications, 1117
  24-hour IOP-lowering effects of latanoprost vs. dorzolamide/timolol, 99
Latitude and uveal melanoma *(Letter)*, 757
Lens of eye
  influence of diabetes mellitus on thickness, shape, and equivalent refractive index of, 1679
  internal lens structure in diabetes mellitus types 1 and 2, 2017
  lens capsule and conjunctival tissues in clinically unilateral pseudoexfoliation syndrome, 614
  multivitamin supplementation for age-related lens opacities, 599
  multivitamin supplements and cataract prevention *(Editorial)*, 597
  retained lens fragments *(Letter)*, 414
  ten-year incidence of age-related cataract and cataract surgery in Australian population, 808
  vitamin E and age-related cataract in randomized trial of women, 822
  vitrectomy and lens status *(Letter)*, 415
Letters to the Editor
  accommodating IOLs, 1850
  acute retinal necrosis, 1104
  acute retinal necrosis in Japan, 1632
  age and refraction, 2097
  AMD genetics, 916
  anesthesia for phacotrabeculectomy, 752
  Artisan phakic IOL, 753
  assessment of glaucoma imaging technology, 1265
  astigmatism and periocular hemangioma, 1854
  autofluorescence imaging, 1853
  bevacizumab and macular edema, 585
  bias and sponsored research, 412
  body mass index and vein occlusion, 917
  cataract surgery complication rates, 1432
  cataract surgery in uveitis, 1431
  charges for cataract surgery, 210
  choroidal nevi in adult Chinese, 1102
  corneal magnification, 588
  corneal thickness, 2315
  cost-effectiveness, 1852
  cost-effectiveness of small-incision cataract surgery, 211
  cost-effectiveness of treating ocular hypertension, 1433
  cryotherapy for pterygia, 2314
  cyclosporine for conjunctival sarcoidosis, 222
  deep anterior lamellar keratoplasty, 1847
  depth of focus, 1438
  diffuse lamellar keratitis, 1848
  DSEK in eyes with double glaucoma tubes, 1435
  ectasia after refractive surgery, 1849
  endophthalmitis, 413
  endothelial keratoplasty, 419
  endothelin-1 in ischemic optic neuropathy, 1262
  episodic anisocoria and anxiety, 1262
  eye drop compliance in religious fasting, 1440
  eye health in East Timor, 1263
  foveal depression and albinism, 756
  gender differences in income, 411
  glass ceiling?, 595
  glaucoma and CSF pressure, 2316, 2317
  glaucoma and mortality, 213
  guidelines for PDT in Japan, 585
  hookworm infestation, 224
  hydroxyapatite orbital implants, 2096, 2320
  infantile orbital cellulitis, 594
  interventions for CRVO, 219
  intraocular telescope, 921
  intraorbital hyaluronic acid for enophthalmos, 1101
  intravenous immunoglobulins and mucous membrane pemphigoid, 752
  intravitreal triamcinolone, 1436
  intravitreal triamcinolone and blood glucose, 916
  iris morphology, 418
  juxtafoveal telangiectasias, 1636
  lacrimal surgery, 759
  latitude and uveal melanoma, 757
  lid reconstruction, 1643
  lines of Blaschko, 1855
  low plus lenses for children, 222
  Merkel cell carcinoma, 1643
  more may be less, 1265
  moxifloxacin for bacterial keratitis, 1103
  mydriasis-induced angle-closure, 1434
  myopia risk factors, 919
  myopic choroidal neovascularization genetics, 1632
  narrow angles, 214
  normal-tension glaucoma, 590
  OCT of corneal opacities, 589
  ocular cicatricial pemphigoid, 1639
  ocular complications of dengue fever, 1100 (erratum, 1524)
  optic nerve cysticercosis, 2094
  optic nerve hemangioblastoma, 2094
  optical coherence tomography, 417
  "optical," not "ocular," coherence tomography, 2095
  outcome measures, 1267
  persistent placoid maculopathy, 220
  phakic IOLs in children, 592
  post hoc power calculations, 2098
  posterior corneal surface, 588
  ptosis after sub–Tenon's capsule triamcinolone, 410
  radial optic neurotomy, 1638
  recurrent idiopathic intracranial hypertension, 221
  reflux after intravitreal injection of bevacizumab, 1268
  refraction after IOL exchange, 754
  refractive error in Myanmar, 1642
  rehabilitation and intraocular telescopes, 1437
  retained lens fragments, 414
  retinal detachment from macular hole, 2318
  retinal endovascular lysis, 216
  scleral buckling vs. vitrectomy, 1634
  secondary cataract prevention, 212
  serpiginous choroiditis, 1633
  small choroidal melanoma, 2319
  spherical aberration and depth of focus, 1641
  Stickler syndrome, 1636
  subthreshold laser, 216
  surgery for optic neuropathy, 1099
  surrogate marker, 416
  talc retinopathy, 755
  timing of detachment surgery, 586
  tip position during phaco, 2314
  trabeculectomy outcomes, 1102
  tropicamide and myopia progression, 1103
  Tulane after Katrina, 922
  ultrasound biomicroscopy in anterior uveitis, 1851
  value-based medicine, 2099
  vitrectomy and lens status, 415
  X-linked retinoschisis, 920
Lichen planus, bicanalicular obstruction in, 386
Lidocaine, supplementary intracameral lidocaine for phacoemulsification under topical anesthesia, 455
Limbal epithelial stem cell transplantation, 1989

Lines of Blaschko *(Letter)*, 1855
Liwan Eye Study, anterior chamber depth in elderly Chinese, 1286
Los Angeles Latino Eye Study
  impact of visual field loss on quality of life in glaucoma, 941
  sociodemographic, family history, and lifestyle risk factors for open-angle glaucoma and ocular hypertension, 639
  type 2 diabetes mellitus and risk of open-angle glaucoma, 227
  visual acuity after cataract extraction in adult Latinos, 815
Lutein, macular carotenoid levels in Japanese ARM patients, 147

M

Macula
  carotenoid levels in Japanese ARM patients, 147
  Fourier-domain OCT and microperimetric findings after macula-off retinal detachment repair, 1923
  macular thickness and diabetic retinopathy severity, 533
  mapping of macular substructures with OCT for glaucoma diagnosis, 949
  persistent placoid maculopathy *(Letter)*, 220
Macular degeneration
  age-related (AMD)
    age–period–cohort effect on incidence of, 1460
    anti-VEGF pharmacotherapy for *(Ophthalmic Technology Assessment)*, 1837
    autofluorescence imaging in AMD with choroidal neovascularization, 342
    CFH and *LOC387715/ARMS2* genotypes and treatment with antioxidants and zinc for, 1019
    complement activation–related diseases and, 1904
    Complications of Age-related Macular Degeneration Prevention Trial, night vision symptoms and progression of AMD, 1876
    cost-utility analysis for treatment of, 2192
    dietary antioxidants and long-term incidence of, 334
    drusen ultrastructure imaging with spectral domain OCT in, 1883
    eye-related Medicare costs for patients with AMD 1995–1999, 18
    genetics of *(Letter)*, 916
    HtrA1 promoter polymorphism, smoking, and AMD, 1891
    inflammation, complement factor H and, 1742
    LOC387715 polymorphism, inflammatory markers, smoking and, 693
    low luminance function and geographic atrophy in, 1480
    neovascular
      alleles in HtrA serine peptidase 1 gene and risk of, 1209
      characteristics of choroidal neovascularization, 1468
      inflammation after intravitreous bevacizumab injections for, 1911
      more intense vs. standard early verteporfin treatment, 134
      natural history and prognosis for, 116 (erratum, 1524)
      OCT after pegaptanib or bevacizumab in, 347
      OCT retinal parameters and visual acuity in, 2206
      risk factors for choroidal neovascularization and geographic atrophy, 1474
      vitreous levels of bevacizumab and VEGF-A in, 1750
    one-year results of PDT in AMD and polypoidal choroidal vasculopathy in Japanese patients, 141
    peripheral reticular pigmentary change and complement factor H Y402H variant in, 520
    prevalence and risk factors in adult Japanese population, 1376
    prevalence in Malay population, 1735
    prevalence of ARM and AMD among Inuit in Greenland, 700
    progress toward personalized medicine for *(Editorial)*, 925
    retinal precursors and development of geographic atrophy in, 1026
    Rotterdam Study, VEGF gene polymorphisms and AMD risk, 1899
    supplements and, 1203
    tachyphylaxis to intravitreal anti-VEGF therapy in, 2199
    vitamin usage patterns in prevention of advanced AMD, 1032
    subfoveal neovascular, value-based medicine analysis of ranibizumab for, 1039
    visual acuity measured with Snellen and Early Treatment Diabetic Retinopathy Study charts, 319
Macular edema
  bevacizumab and *(Letter)*, 585
  cystoid, 3D OCT imaging in retinal vein occlusion, 355
  diabetic
    analysis methods in OCT studies of, 1366
    intravitreal triamcinolone acetonide vs. focal/grid photocoagulation for, 1447
    macular thickness and diabetic retinopathy severity, 533
    a new look at an old treatment for *(Editorial)*, 1445
    OCT in *(Letter)*, 417
    surrogate marker for visual function *(Letter)*, 416
Macular hole
  fellow eye findings in high myopic retinal detachment with, 1489
  results after second surgery for, 158
  retinal detachment from *(Letter)*, 2318
  vitrectomy for symptomatic lamellar macular hole, 884
Maculopathy, age-related (ARM)
  carotenoids and antioxidants in, 324
  macular carotenoid levels in Japanese patients with, 147
  macular pigment density and, 876
  prevalence of ARM and AMD among Inuit in Greenland, 700
Magnetic resonance imaging
  functional anatomy of inferior rectus muscle in superior oblique muscle palsy, 2079
  retrobulbar hemangioblastomas in von Hippel–Lindau disease, 1382
Managed care, direct costs of blindness experienced by patients enrolled in, 11
Mandating comprehensive eye examinations for children *(Editorial)*, 1271
Medical education, national program director survey of shift to competency-based education in ophthalmology, 1426
Medicare beneficiaries
  eye-related Medicare costs for patients with AMD 1995–1999, 18
  longitudinal rates of postoperative adverse outcomes after glaucoma surgery, 1109
  rates of glaucoma medication utilization in primary open-angle glaucoma, 1315
  trab vs. tube, a 15-year retrospective *(Editorial)*, 1107
Meibomian glands, age-related changes of, 911
Meiktila Eye Study, refractive error in rural Myanmar, 26
Melanoma
  baseline echographic characteristics of tumors in Collaborative Ocular Melanoma Study, 1390
  conjunctival primary acquired melanosis and risks for progression to, 511
  latitude and *(Letter)*, 757
  modeling survival from choroidal melanoma with neural networks, 1598
  routes of extraocular extension of, 1778
  small choroidal *(Letter)*, 2319
  square procedure for periocular cutaneous melanoma, 2295
Melanosis, primary acquired conjunctival, and risks for progression to melanoma, 511
Melphalan, intraarterial, for intraocular retinoblastoma, 1398
Merkel cell carcinoma
  of eyelid, 195
  (Letter), 1643
Metabolic syndrome components and risk of cataract extraction in women, 1687
Methotrexate, for noninfectious ocular inflammation, 1826
Modeling survival from choroidal melanoma with neural networks, 1598

Monitoring
for endophthalmitis and other cataract surgery complications, 3
identification of cataract in patients with neovascular maculopathy, 127
Mortality
glaucoma and *(Letter)*, 213
topical β-blockers and, 2037
visual acuity and mortality in Chinese population, 802
Mosaic retinal dysfunction in choroideremia carriers, 723
Motor vehicle accidents, seatbelt use, airbag deployment, and ocular injuries, 573
Moxifloxacin, for bacterial keratitis *(Letter)*, 1103
Mucous membrane pemphigoid
immunosuppressive therapy for, 253, 2146
intravenous immunoglobulins and *(Letter)*, 752
Multi-Ethnic Pediatric Eye Disease Study
amblyopia and strabismus in African American and Hispanic children, 1229
testability of Retinomax Autorefractor and IOLMaster in preschool children, 1422
Multi-Ethnic Study of Atherosclerosis, inflammation, complement factor H, and AMD, 1742
Multivitamin supplementation
for age-related lens opacities, 599
and cataract prevention *(Editorial)*, 597
Myasthenia gravis, pediatric ocular, 1245
Mycophenolate mofetil
after methotrexate for scleritis and uveitis, 1416
for noninfectious ocular inflammation, 1826
for ocular mucous membrane pemphigoid, 253
Mydriasis-induced angle-closure *(Letter)*, 1434
Myopia
Epi-LASIK vs. off-flap Epi-LASIK for low and moderate myopia, 2174
evaluation of internal refraction with optical path difference scan, 57
fellow eye findings in high myopic retinal detachment with macular hole, 1489
five-year follow-up of 399 Artisan–Verisyse phakic IOLs for, 1002
five-year outcome of LASIK for, 839
genetic dissection of, 1053
myopic choroidal neovascularization genetics *(Letter)*, 1632
OCT detection of paravascular lamellar holes in high myopia, 708
outdoor activity and myopia prevalence in children, 1279
prevalence and risk factors in Singapore Malay Eye Study, 1713
progression of myopia in ROP, 1058
refractive error in rural Myanmar, 26
risk factors for *(Letter)*, 919
safety of overnight orthokeratology for *(Ophthalmic Technology Assessment)*, 2301
season of birth, natural light and, 686
three-year results of Artisan/Verisyse phakic IOL implantation, 464
tropicamide and progression of *(Letter)*, 1103
wavefront-guided LASIK for correction of primary myopia and astigmatism *(Ophthalmic Technology Assessment)*, 1249
Myxofibrosarcoma of orbit, 1237

N

NAION, Se Nonarteritic anterior ischemic optic neuropathy
Nasolacrimal duct obstruction. *See also* Lacrimal system
premature silicone stent loss after dacryocystorhinostomy, 1241
treatment with probing in children younger than 4 years, 577
Neovascularization
alleles in HtrA serine peptidase 1 gene and risk of neovascular AMD, 1209
autofluorescence imaging in AMD with, 342
cardiovascular disease, hypertension, and choroidal neovascularization, 1046
characteristics of choroidal neovascularization in AMD, 1468
identification of cataract in patients with neovascular maculopathy, 127
intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma, 1571
more intense vs. standard early verteporfin treatment of neovascular AMD, 134
myopic choroidal neovascularization genetics *(Letter)*, 1632
natural history and prognosis for neovascular AMD, 116 (erratum, 1524)
OCT after pegaptanib or bevacizumab in neovascular AMD, 347
OCT retinal parameters and visual acuity in neovascular AMD, 2206
risk factors for choroidal neovascularization and geographic atrophy in AMD, 1474
surgical removal of peripapillary choroidal neovascularization in presumed ocular histoplasmosis syndrome, 540
value-based medicine analysis of ranibizumab for subfoveal neovascular macular degeneration, 1039
vitreous cavity hemorrhage after diabetic vitrectomy, 525
vitreous levels of bevacizumab and VEGF-A in choroidal neovascularization, 1750
Nerves and innervation
multidetector CT angiography in isolated third nerve palsy, 1411
natural history of visual outcome in NAION, 298
optic disc and peripapillary morphology in NAION, 1585
optic nerve head topography and visual field in open-angle and angle-closure glaucoma, 239
retinal nerve fiber structure vs. visual field function in ischemic optic neuropathy, 904
surgery for optic neuropathy *(Letter)*, 1099
visual function 15 years after optic neuritis, 1079
visual function–optic nerve structure correlation, 440
Neurodevelopment in children with albinism, 1805
Nevi, choroidal
in adult Chinese *(Letter)*, 1102
clinical spectrum of, 546
Night vision symptoms and progression of AMD, 1876
Nomenclature, American Academy of Ophthalmology adopts SNOMED CT as its official clinical terminology *(Editorial)*, 225
Nonarteritic anterior ischemic optic neuropathy (NAION)
in diabetic patients, 1818
endothelin-1 in *(Letter)*, 1262
natural history of visual outcome, 298
optic disc and peripapillary morphology in, 1585
refractive error and its relationship to cup/disc ratio, 2275
surgery for *(Letter)*, 1099
visual fields at follow-up in Ischemic Optic Neuropathy Decompression Trial, 1809
Norrie disease, ophthalmic examination and carrier status for gene mutation, 730

O

OAG. *See* Glaucoma, open-angle
OCT. *See* Optical coherence tomography
Ocular alignment in childhood esotropia, 2266
Ocular biometry, testability of Retinomax Autorefractor and IOLMaster in preschool children, 1422
Ocular cicatricial pemphigoid *(Letter)*, 1639
Ocular hypertension. *See also* Glaucoma
cost-effectiveness of treatment, 94 (erratum, 1524) *(Letter)*, 1433
health care charges for patients with, 633
IOP-lowering efficacy of brinzolamide/timolol, 1728

long-term IOP fluctuations and risk of conversion from ocular hypertension to glaucoma, 934
Ocular Hypertension Treatment Study, changes in central corneal thickness over time, 1550
predictive models for open-angle glaucoma in, 2030
sociodemographic, family history, and lifestyle risk factors for, 639
24-hour IOP-lowering effects of latanoprost vs. dorzolamide/timolol, 99
Ocular surface
tacrolimus ointment for refractory ocular surface inflammatory diseases, 988
topical interferon alfa-2b vs. surgical excision for primary ocular surface squamous neoplasia, 1297
of treated glaucoma patients expresses CCR5 and CCR4, 109
Operations Iraqi and Enduring Freedom
combat ocular trauma visual outcomes during, 2235
perforating globe injuries during, 2087
severe eye injuries in, 377
Ophthalmic Technology Assessment
anti-VEGF pharmacotherapy for AMD, 1837
aqueous shunts in glaucoma, 1089
orbital radiation for Graves' ophthalmopathy, 398
safety of overnight orthokeratology for myopia, 2301
wavefront-guided LASIK for correction of primary myopia and astigmatism, 1249
Ophthalmologists
adoption and perceptions of electronic health record systems by, 1591
gender differences in income *(Letter)*, 411
glass ceiling? *(Letter)*, 595
improving patient-centered care *(Editorial)*, 1645
national program director survey of shift to competency-based education, 1426
patient satisfaction with quality of care provided by ophthalmology residents, 738
Ophthalmology
editorial board for 2008, 2322
increased transparency: making the journal better for readers and for authors *(Editorial)*, 1443
scientific reviewers for 2008, 2322
Ophthalmoplegia, diplopia, blepharoptosis, and statin use, 2282
Optic chiasm, nonuniform pressure generation in bitemporal hemianopsia, 560
Optic disc
disc hemorrhages and treatment in Early Manifest Glaucoma Trial, 2044
hemorrhage in primary angle-closure glaucoma, 1328
HRT 3 diagnostic accuracy across disc sizes and glaucoma stages, 1358
optic disc hemorrhage associated with RNFL loss, 2132
and peripapillary morphology in NAION, 1585
refractive error in NAION and its relationship to cup/disc ratio, 2275
retinal area/optic disc rim area ratio in amblyopia, 2259
RNFL vs. optic disc imaging for glaucoma diagnosis, 1340
Optic nerve
cysticercosis of *(Letter)*, 2094
endothelin-1 in ischemic optic neuropathy *(Letter)*, 1262
hemangioblastoma of *(Letter)*, 2094
NAION in diabetic patients, 1818
natural history of visual outcome in NAION, 298
optic disc and peripapillary morphology in NAION, 1585
optic nerve head topography and visual field in open-angle and angle-closure glaucoma, 239
retinal nerve fiber structure vs. visual field function in ischemic optic neuropathy, 904
surgery for optic neuropathy *(Letter)*, 1099
visual fields at follow-up in Ischemic Optic Neuropathy Decompression Trial, 1809
visual function 15 years after optic neuritis, 1079
visual function–optic nerve structure correlation, 440
Optical coherence tomography (OCT)
adaptive optics images of localized photoreceptor changes, 1771
analysis methods in OCT studies of diabetic macular edema, 1366
central corneal thickness measurement with slip-lamp OCT vs. Visante OCT, 796
combining RNFL parameters to optimize glaucoma diagnosis with, 1352
of corneal opacities *(Letter)*, 589
detection of changes in juvenile crystalline macular dystrophy in Sjögren–Larsson syndrome, 870
in diabetic macular edema *(Letter)*, 417
drusen ultrastructure imaging with spectral domain OCT in AMD, 1883
enhanced retinal imaging with spectral-domain OCT with multiple B-scan averaging, 1071
Fourier-domain OCT and microperimetric findings after macula-off retinal detachment repair, 1923
gonioscopy vs. anterior segment OCT in detecting angle closure in different quadrants of anterior chamber angle, 769
high-speed, ultrahigh-resolution, for visualization of glaucomatous retinal damage, 782
keratoconus diagnosis with OCT pachymetry mapping, 2159
mapping of macular substructures with OCT for glaucoma diagnosis, 949
of morphologic changes in central serous chorioretinopathy, 1494
OCT and histopathology of sutureless vitrectomy wounds, 2221
OCT detection of paravascular lamellar holes in high myopia, 708
OCT retinal parameters and visual acuity in neovascular AMD, 2206
optic disc hemorrhage associated with RNFL loss, 2132
"optical," not "ocular," coherence tomography *(Letter)*, 2095
after pegaptanib or bevacizumab in neovascular AMD, 347
relationship between RNFL measurement and signal strength in, 1347
reproducibility of peripapillary RNFL thickness measurements with Stratus OCT in glaucoma, 661
tachyphylaxis to intravitreal anti-VEGF therapy in AMD, 2199
in talc retinopathy *(Letter)*, 755
3D imaging of cystoid macular edema in retinal vein occlusion, 355
ultrasound pachymetry and OCT measurements of central corneal thickness *(Letter)*, 2315
vitrectomy for symptomatic lamellar macular hole, 884
vitreous surgery in X-linked retinoschisis, 718
Optical path difference scan, 57
Optimizing outcomes *(Editorial)*, 1
Orbital cellulitis, infantile *(Letter)*, 594
Orbital floor fractures, CT underestimation of soft tissue entrapment in pediatric patients, 1620
Orbital implants
exposure rate of hydroxyapatite implants over 15 years, 566
hydroxyapatite *(Letter)*, 2096, 2320
Orbital lymphoproliferative tumors, 1626
Outdoor activity and myopia prevalence in children, 1279
Overnight orthokeratology for myopia, safety of *(Ophthalmic Technology Assessment)*, 2301
Oxidative stress, vitreous levels of reactive oxygen species in proliferative diabetic retinopathy, 734
Oxygen saturation, cerebral blood flow, and retinal vessel diameters, 887

P

Paravascular lamellar holes, in high myopia, OCT detection of, 708
Patient opinions of clinical tests used in glaucoma management, 2127

Patient satisfaction with quality of care provided by ophthalmology residents, 738
PDT. *See* Photodynamic therapy
Pediatric population
amblyopia and strabismus in African American and Hispanic children, 1229
anterior uveitis in juvenile idiopathic arthritis, 1833
Baltimore Pediatric Eye Disease Study
low concordance of fixation preference with visual acuity in preschool children, 1796
prevalence of decreased vision in preschool children, 1786
conservative treatments for intraocular retinoblastoma, 1405
CT underestimation of soft tissue entrapment in pediatric orbital floor fractures, 1620
glaucoma after surgery for congenital cataract, 1013
infantile orbital cellulitis *(Letter)*, 594
instability of ocular alignment in childhood esotropia, 2266
intraarterial melphalan for intraocular retinoblastoma, 1398
intralesional corticosteroids for astigmatism induced by periocular capillary hemangioma, 390
Joubert syndrome, 2286
low plus lenses for children *(Letter)*, 222
mandating comprehensive eye examinations for children *(Editorial)*, 1271
mydriasis-induced angle-closure *(Letter)*, 1434
nasolacrimal duct probing in children younger than 4 years, 577
near vs. far distance activities while patching for amblyopia, 2071
neurodevelopment in children with albinism, 1805
new eye lesions in treated congenital toxoplasmosis, 553
outcomes of ocular myasthenia gravis in, 1245
outdoor activity and myopia prevalence in, 1279
phakic IOLs in *(Letter)*, 592
prevalence of hyperopia in 6- and 12-year-olds, 678
progression of myopia in ROP, 1058
scleral fixation of posterior chamber IOLs in children, 67
telemedical diagnosis of ROP, 1222
Tessier number 10 clefts, 2290
testability of Retinomax Autorefractor and IOLMaster in preschool children, 1422
variability of control in intermittent exotropia, 371
vitreous levels of SDF-1α and VEGF in ROP, 1065
Pegaptanib
anti-VEGF pharmacotherapy for AMD *(Ophthalmic Technology Assessment)*, 1837
OCT after pegaptanib or bevacizumab in neovascular AMD, 347
Penetrating keratoplasty (PK)
in Asian eyes, 975
comparison of posterior lamellar keratoplasty techniques to, 1525
same-sizing vs. oversizing donor trephines in keratoconic patients undergoing, 268
traumatic graft dehiscence after, 276
Pentacam, keratoconus detection by posterior corneal elevation with, 1534
P.E.R.F.E.C.T. technique, prospective study of pterygium extended removal followed by extended conjunctival transplantation, 1663
Perifosine, ulcerative keratitis in GIST patients treated with, 483
Perimetry, patient opinions of clinical tests used in glaucoma management, 2127
Peripheral iridotomy, vs. early phacoemulsification to prevent IOP rise after acute primary angle closure, 1134
Persistent placoid maculopathy *(Letter)*, 220
Phacoemulsification
anesthesia for phacotrabeculectomy *(Letter)*, 752
vs. combined phacotrabeculectomy in chronic angle closure glaucoma with cataract, 2167
comparison of 1-site and 2-site phacotrabeculectomy, 447, 1130
comparison of 1-site and 2-site phacotrabeculectomy procedures, 447, 1130
early, vs. peripheral iridotomy to prevent IOP rise after acute primary angle closure, 1134
retained lens fragments after *(Letter)*, 414
tip position during *(Letter)*, 2314
under topical anesthesia, supplementary intracameral lidocaine for, 455
Pharmaceutical companies, bias and sponsored research *(Letter)*, 412
Pharmacology, mechanism of action of bimatoprost, latanoprost, and travoprost, 790
Photodynamic therapy (PDT)
guidelines for PDT in Japan *(Letter)*, 585
half-dose verteporfin PDT for central serous chorioretinopathy, 1756
more intense vs. standard early verteporfin treatment of neovascular AMD, 134
one-year results in AMD and polypoidal choroidal vasculopathy in Japanese patients, 141
Photoreceptors, adaptive optics images of localized changes of, 1771
Photorefractive keratectomy, risk assessment for ectasia after corneal refractive surgery, 37
Pigmentation
iris morphology *(Letter)*, 418
macular pigment density and ARM, 876
peripheral reticular pigmentary change and complement factor H Y402H variant in AMD, 520
pigmented squamous cell carcinoma in situ of conjunctiva, 1673
PK. *See* Penetrating keratoplasty
Population studies
Barbados Eye Studies
pterygium incidence and risk factors in, 2153
risk factors for incident open-angle glaucoma, 85
Beaver Dam Eye Study
age–period–cohort effect on incidence of AMD, 1460
incidence of age-related cataract over 15-year interval, 477
supplements and age-related eye conditions, 1203
Blue Mountains Eye Study
dietary antioxidants and long-term incidence of AMD, 334
LOC387715 polymorphism, inflammatory markers, smoking, and AMD, 693
retinal vessel caliber and incidence of age-related cataract, 1693
ten-year incidence of age-related cataract and cataract surgery in Australian population, 808
central serous chorioretinopathy in Olmsted County, MN, 1980–2002, 169
Chennai Glaucoma Study
prevalence of open-angle glaucoma in South India, 648
prevalence of primary angle-closure glaucoma in South India, 655
Funagata Study, prevalence and risk factors for AMD in adult Japanese population, 1376
Greenland Inuit Eye Study, prevalence of ARM and AMD, 700
Handan Eye Study, low vision and blindness in rural Chinese adults, 1965
Los Angeles Latino Eye Study
impact of visual field loss on quality of life in glaucoma, 941
sociodemographic, family history, and lifestyle risk factors for open-angle glaucoma and ocular hypertension, 639
type 2 diabetes mellitus and risk of open-angle glaucoma, 227
visual acuity after cataract extraction in adult Latinos, 815
Meiktila Eye Study, refractive error in rural Myanmar, 26
metabolic syndrome components and risk of cataract extraction in women, 1687
Multi-Ethnic Pediatric Eye Disease Study
amblyopia and strabismus in African American and Hispanic children, 1229

testability of Retinomax Autorefractor and IOLMaster in preschool children, 1422
Multi-Ethnic Study of Atherosclerosis, inflammation, complement factor H, and AMD, 1742
prevalence of hyperopia in 6- and 12-year-olds, 678
rapid assessment of avoidable blindness in Kunming, China, 969
relationship of 10-year change in refraction to nuclear cataract and axial length, 1273
Rotterdam Study
oxygen saturation, cerebral blood flow, and retinal vessel diameters, 887
VEGF gene polymorphisms and AMD risk, 1899
season of birth, natural light, and myopia, 686
Singapore Malay Eye Study
diabetes, hyperglycemia, and central corneal thickness, 964
prevalence and risk factors for diabetic retinopathy, 1869
prevalence and risk factors for refractive errors in, 1713
prevalence of AMD in, 1735
vision impairment, ocular conditions, and vision-specific function, 1973
Tajimi Study, refractive errors in elderly Japanese population, 363
Tanjong Pagar Study, visual acuity and mortality in Chinese population, 802
techniques to monitor for endophthalmitis and other cataract surgery complications, 3
topical β-blockers and mortality, 2037
utility of symptoms in identification of primary angle-closure, 2024
Wisconsin Epidemiologic Study of Diabetic Retinopathy
25-year progression of retinopathy in type 1 diabetes, 1859 *(Editorial)*, 1857
Posterior capsular opacification
effect of AcrySof vs. silicone or polymethyl methacrylate IOL on, 830
optic edge design as long-term factor for, 1308
Prednisone, for ocular mucous membrane pemphigoid, 2146
Preferred practice patterns (PPPs)–twenty years and counting *(Editorial)*, 2125
Procedures
adaptive optics images of localized photoreceptor changes, 1771
assessment of glaucoma imaging technology *(Letter)*, 1265
central corneal thickness measurement with slip-lamp OCT vs. Visante OCT, 796
comparison of parameters from HRT versions 2 and 3, 673
comparison of posterior lamellar keratoplasty techniques to PK, 1525
corneal in vivo confocal scanning laser microscopy in atopic keratoconjunctivitis, 2004
diagnostic capability of scanning laser polarimetry in early open-angle glaucoma, 1167
drusen ultrastructure imaging with spectral domain OCT in AMD, 1883
endothelial keratoplasty, 1179
enhanced retinal imaging with spectral-domain OCT with multiple B-scan averaging, 1071
evaluation of internal refraction with optical path difference scan, 57
femtosecond laser–assisted sutureless anterior lamellar keratoplasty, 1303
gonioscopy vs. anterior segment OCT in detecting angle closure in different quadrants of anterior chamber angle, 769
high-speed ultrahigh-resolution OCT for visualization of glaucomatous retinal damage, 782
HRT 3 diagnostic accuracy across disc sizes and glaucoma stages, 1358
HRT 3 in discriminating between normal and glaucoma-damaged eyes, 775
identification of cataract in patients with neovascular maculopathy, 127
keratoconus detection by posterior corneal elevation with Pentacam, 1534
keratoconus diagnosis with OCT pachymetry mapping, 2159
mapping of macular substructures with OCT for glaucoma diagnosis, 949
orbital radiation for Graves' ophthalmopathy *(Ophthalmic Technology Assessment)*, 398
prospective study of pterygium extended removal followed by extended conjunctival transplantation, 1663
radial optic neurotomy, 174
radial optic neurotomy *(Letter)*, 1638
reproducibility of pattern ERG in glaucoma, 957
reproducibility of peripapillary RNFL thickness measurements with Stratus OCT in glaucoma, 661
retinal endovascular lysis *(Letter)*, 216
RNFL vs. optic disc imaging for glaucoma diagnosis, 1340
sandwich technique for eyelid reconstruction, 189
scanning laser polarimetry with variable corneal compensation in primary angle-closure glaucoma, 1334
screening for narrow angles in Singapore population, 1720
subthreshold diode micropulse photocoagulation for central serous chorioretinopathy, 2229
subthreshold laser irradiation *(Letter)*, 216
superior oblique tendon suture spacer for Brown syndrome, 1800
temporal fossa decompression for disfiguring thyroid-related orbitopathy, 1613
transscleral cyclodiode laser photocoagulation in aqueous misdirection syndrome, 2058
visual acuity in macular degeneration patients measured with Snellen and Early Treatment Diabetic Retinopathy Study charts, 319
wavefront-guided LASIK for correction of primary myopia and astigmatism *(Ophthalmic Technology Assessment)*, 1249
Proliferative vitreoretinopathy, adjunctive triamcinolone acetonide in silicone-filled eyes for, 1938
Prostaglandin analogs
mechanism of action of bimatoprost, latanoprost, and travoprost, 790
24-hour IOP-lowering effects of latanoprost vs. dorzolamide/timolol, 99
Pseudoexfoliation syndrome
clinically unilateral, lens capsule and conjunctival tissues in, 614
sensorineural hearing loss in, 425
Pterygium
cryotherapy for *(Letter)*, 2314
incidence and risk factors in Barbados Eye Studies, 2153
prospective study of pterygium extended removal followed by extended conjunctival transplantation, 1663

Q

Quality of care
improving patient-centered care *(Editorial)*, 1645
PPPs–twenty years and counting *(Editorial)*, 2125
provided by ophthalmology residents, 738
Quality of life
glaucoma and, 233
impact of anchor point on utilities for 5 common diseases, 898
impact of visual field loss on quality of life in glaucoma, 941

R

Race/ethnicity
Barbados Eye Studies
pterygium incidence and risk factors in, 2153
risk factors for incident open-angle glaucoma, 85
Behçet's disease in Chinese patients, 312
choroidal nevi in adult Chinese *(Letter)*, 1102
guidelines for PDT in Japan *(Letter)*, 585
keratoprosthesis surgery for end-stage corneal blindness in Asian population, 503

Los Angeles Latino Eye Study
impact of visual field loss on quality of life in glaucoma, 941
sociodemographic, family history, and lifestyle risk factors for open-angle glaucoma and ocular hypertension, 639
type 2 diabetes mellitus and risk of open-angle glaucoma, 227
visual acuity after cataract extraction in adult Latinos, 815
macular carotenoid levels in Japanese ARM patients, 147
Multi-Ethnic Pediatric Eye Disease Study
amblyopia and strabismus in African American and Hispanic children, 1229
testability of Retinomax Autorefractor and IOLMaster in preschool children, 1422
Multi-Ethnic Study of Atherosclerosis, inflammation, complement factor H, and AMD, 1742
one-year results of PDT in AMD and polypoidal choroidal vasculopathy in Japanese patients, 141
rapid assessment of avoidable blindness in Kunming, China, 969
refractive errors in elderly Japanese population, 363
Singapore Corneal Transplant Study, PK in Asian eyes, 975
Singapore Malay Eye Study
diabetes, hyperglycemia, and central corneal thickness, 964
prevalence and risk factors for diabetic retinopathy, 1869
prevalence and risk factors for refractive errors in, 1713
prevalence of AMD in, 1735
vision impairment, ocular conditions, and vision-specific function, 1973
visual acuity and mortality in Chinese population, 802
Radial optic neurotomy, 174
(Letter), 1638
Radiation therapy for Graves' ophthalmopathy *(Ophthalmic Technology Assessment)*, 398
Randomized, controlled trials (RCTs)
adjunctive triamcinolone acetonide in silicone-filled eyes for proliferative vitreoretinopathy, 1938
CFH and *LOC387715/ARMS2* genotypes and treatment with antioxidants and zinc for AMD, 1019
comparing ICU accommodative, multifocal, and monofocal IOLs, 993
comparison of 1-site and 2-site phacotrabeculectomy, 447, 1130
donor age and corneal endothelial cell loss after corneal transplantation, 627
donor age and corneal transplantation outcome, 620
early phacoemulsification vs. peripheral iridotomy to prevent IOP rise after acute primary angle closure, 1134
effect of nilvadipine on visual field and ocular circulation in glaucoma, 2049
Epi-LASIK vs. off-flap Epi-LASIK for low and moderate myopia, 2174
half-dose verteporfin PDT for central serous chorioretinopathy, 1756
intravitreal triamcinolone acetonide vs. focal/grid photocoagulation for diabetic macular edema, 1447
more intense vs. standard early verteporfin treatment of neovascular AMD, 134
multivitamin supplementation for age-related lens opacities, 599
near vs. far distance activities while patching for amblyopia, 2071
one-year outcomes with new-generation multifocal IOLs, 1508
phacoemulsification vs. combined phacotrabeculectomy in chronic angle closure glaucoma with cataract, 2167
supplementary intracameral lidocaine for phacoemulsification under topical anesthesia, 455
visual fields at follow-up in ischemic Optic Neuropathy Decompression Trial, 1809
vitamin E and age-related cataract in randomized trial of women, 822
Ranibizumab
anti-VEGF pharmacotherapy for AMD *(Ophthalmic Technology Assessment)*, 1837
intravitreal, for retinal capillary hemangioblastoma in von Hippel-Lindau disease, 1957
for subfoveal neovascular macular degeneration, value-based medicine analysis of, 1039
RCTs. *See* Randomized, controlled trials
Reactive oxygen species, vitreous levels in proliferative diabetic retinopathy, 734
Refraction
age and *(Letter)*, 2097
evaluation of internal refraction with optical path difference scan, 57
influence of diabetes mellitus on thickness, shape, and equivalent refractive index of lens, 1679
Refractive error
in elderly Japanese population, 363
fellow eye findings in high myopic retinal detachment with macular hole, 1489
five-year follow-up of 399 Artisan–Verisyse phakic IOLs for, 1002
genetic dissection of myopia, 1053
low plus lenses for children *(Letter)*, 222
in Myanmar *(Letter)*, 1642
myopia risk factors *(Letter)*, 919
myopic choroidal neovascularization genetics *(Letter)*, 1632
OCT detection of paravascular lamellar holes in high myopia, 708
outdoor activity and myopia prevalence in children, 1279
prevalence and risk factors in Singapore Malay Eye Study, 1713
prevalence of hyperopia in 6- and 12-year-olds, 678
progression of myopia in ROP, 1058
refraction after IOL exchange *(Letter)*, 754
refractive error in NAION and its relationship to cup/disc ratio, 2275
relationship of 10-year change in refraction to nuclear cataract and axial length, 1273
in rural Myanmar, 26
safety of overnight orthokeratology for myopia *(Ophthalmic Technology Assessment)*, 2301
season of birth, natural light, and myopia, 686
testability of Retinomax Autorefractor and IOLMaster in preschool children, 1422
tropicamide and myopia progression *(Letter)*, 1103
Refractive surgery
corneal ectasia after excimer laser keratorefractive surgery, 2181
corneal magnification and *(Letter)*, 588
ectasia after *(Letter)*, 1849
Epi-LASIK vs. off-flap Epi-LASIK for low and moderate myopia, 2174
five-year outcome of LASIK for myopia, 839
monovision in LASIK, 1196
posterior corneal surface after *(Letter)*, 588
rainbow glare as optical side effect of IntraLASIK, 1187
risk assessment for ectasia after, 37
wavefront-guided LASIK for correction of primary myopia and astigmatism *(Ophthalmic Technology Assessment)*, 1249
Rehabilitation and intraocular telescopes *(Letter)*, 1437
Religious fasting, eye drop compliance in *(Letter)*, 1440
Retinal capillary hemangioblastomas in von Hippel–Lindau disease, 181
intravitreal ranibizumab for, 1957
Retinal detachment
fellow eye findings in high myopic retinal detachment with macular hole, 1489
Fourier-domain OCT and microperimetric findings after macula-off retinal detachment repair, 1923
higher-order aberrations after scleral buckling surgery for, 1216
from macular hole *(Letter)*, 2318
prophylaxis in type 1 Stickler syndrome, 164
scleral buckling vs. vitrectomy for *(Letter)*, 1634
in Stickler syndrome *(Editorial)*, 1636
timing of detachment surgery *(Letter)*, 586

Retinal nerve fiber layer (RNFL)
combining RNFL parameters to optimize glaucoma diagnosis with OCT, 1352
optic disc hemorrhage associated with RNFL loss, 2132
relationship between RNFL measurement and signal strength in OCT, 1347
reproducibility of peripapillary RNFL thickness measurements with Stratus OCT in glaucoma, 661
retinal nerve fiber structure vs. visual field function in ischemic optic neuropathy, 904
RNFL vs. optic disc imaging for glaucoma diagnosis, 1340
Retinal pigment epithelium (RPE)
combined hamartoma of retina and, 2246
OCT of morphologic changes in central serous chorioretinopathy, 1494
Retinal vessels
blood flow response to posture change in glaucoma, 246
Blue Mountains Eye Study, retinal vessel caliber and incidence of age-related cataract, 1693
body mass index and vein occlusion *(Letter)*, 917
central retinal vein occlusion
interventions for *(Letter)*, 219
radial optic neurotomy for, 174
oxygen saturation, cerebral blood flow, and diameters of, 887
retinal endovascular lysis *(Letter)*, 216
retinal vasculature as a fractal, 1951
3D OCT imaging of cystoid macular edema in retinal vein occlusion, 355
Retinoblastoma
conservative treatments for, 1405
diffuse infiltrating, clinical spectrum of, 2253
intraarterial melphalan for, 1398
Retinopathy of prematurity (ROP)
progression of myopia in, 1058
telemedical diagnosis of, 1222
vitreous levels of SDF-1α and VEGF in, 1065
Retinoschisis, X-linked
(Letter), 920
vitreous surgery in, 718
RNFL. *See* Retinal nerve fiber layer
ROB03 gene, bilateral synergistic convergence associated with homozygous mutation of, 2262
ROP. *See* Retinopathy of prematurity
Rotterdam Study
oxygen saturation, cerebral blood flow, and retinal vessel diameters, 887
VEGF gene polymorphisms and AMD risk, 1899
RPE. *See* Retinal pigment epithelium

S

Saccadic dysfunction, in Joubert syndrome, 2286
Safety of overnight orthokeratology for myopia *(Ophthalmic Technology Assessment)*, 2301
Salisbury Eye Evaluation, glaucoma and quality of life, 233
Sandwich technique for eyelid reconstruction, 189
Sarcoidosis, conjunctival, cyclosporine for *(Letter)*, 222
Scanning laser polarimetry
diagnostic capability in early open-angle glaucoma, 1167
with variable corneal compensation in primary angle-closure glaucoma, 1334
Scleral buckling surgery
higher-order aberrations after, 1216
vs. vitrectomy *(Letter)*, 1634
Scleral fixation of posterior chamber IOLs in children, 67
Scleritis, mycophenolate mofetil after methotrexate for uveitis and, 1416
Sclerokeratitis, postkeratoplasty atopic, in keratoconus patients, 851
SDF-1α. *See* Stromal cell–derived factor 1α
Season of birth, natural light, and myopia, 686
Seatbelt use, airbag deployment, and ocular injuries, 573
Sensorineural hearing loss, in pseudoexfoliation syndrome, 425
Serpiginous choroiditis *(Letter)*, 1633
Singapore Corneal Transplant Study, PK in Asian eyes, 975
Singapore Malay Eye Study
diabetes, hyperglycemia, and central corneal thickness, 964
prevalence and risk factors for diabetic retinopathy, 1869
prevalence and risk factors for refractive errors in, 1713
prevalence of AMD in, 1735
vision impairment, ocular conditions, and vision-specific function, 1973
Sjögren–Larsson syndrome, OCT detection of changes in juvenile crystalline macular dystrophy in, 870
Smoking
HtrA1 promoter polymorphism, smoking, and AMD, 1891
LOC387715 polymorphism, inflammatory markers, smoking, and AMD, 693
Snellen chart, visual acuity in macular degeneration patients measured with Early Treatment Diabetic Retinopathy Study chart and, 319
Soft tissue entrapment in pediatric orbital floor fractures, CT underestimation of, 1620
Spectacles, low plus lenses for children *(Letter)*, 222
Spherical aberration and depth of focus *(Letter)*, 1641
Squamous cell carcinoma in situ of conjunctiva, pigmented, 1673
Squamous neoplasia of ocular surface, topical interferon alfa-2b vs. surgical excision for, 1297
Statin drugs, diplopia, blepharoptosis, ophthalmoplegia and use of, 2282
Statistics
hypothesis testing, confidence intervals and power of clinical studies, 423
optimizing outcomes *(Editorial)*, 1
post hoc power calculations *(Letter)*, 2098
Stereopsis, after surgery to remove a unilateral epiretinal membrane, 1930
Stickler syndrome
(Editorial), 1636
retinal detachment prophylaxis in, 164
Strabismus
and amblyopia in African American and Hispanic children, 1229
near vs. far distance activities while patching for amblyopia, 2071
variability of control in intermittent exotropia, 371
Stromal cell–derived factor 1α (SDF-1α) and VEGF, vitreous levels in ROP, 1065
Subthreshold laser irradiation *(Letter)*, 216
Superior oblique muscle palsy, functional anatomy of inferior rectus muscle in, 2079
Superior oblique tendon suture spacer for Brown syndrome, 1800
Sydney Myopia Study, outdoor activity and myopia prevalence in children, 1279
Synergistic convergence associated with homozygous *ROB03* mutation, 2262

T

Tacrolimus ointment, for refractory ocular surface inflammatory diseases, 988
Tajimi Study, refractive errors in elderly Japanese population, 363
Talc retinopathy *(Letter)*, 755
Tanjong Pagar Study, visual acuity and mortality in Chinese population, 802
Telemedical diagnosis of ROP, 1222
Telescope, intraocular *(Letter)*, 921, 1437

Temporal fossa decompression for disfiguring thyroid-related orbitopathy, 1613
Terminology, American Academy of Ophthalmology adopts SNOMED CT as its official clinical terminology *(Editorial)*, 225
Tessier number 10 clefts, 2290
Third nerve palsy, isolated, multidetector CT angiography in, 1411
Thyroid disease
  eyelid retraction, lid lag, lagophthalmos, and von Graefe's sign in thyroid eye disease, 1083
  hypothyroidism and open-angle glaucoma in elderly population, 1581
  orbital radiation for Graves' ophthalmopathy *(Ophthalmic Technology Assessment)*, 398
  temporal fossa decompression for, 1613
Timolol
  IOP-lowering efficacy of brinzolamide and, 1728
  meta-analysis of 24-hour IOP studies evaluating efficacy of glaucoma medications, 1117
  24-hour IOP-lowering effects of latanoprost vs. dorzolamide/timolol, 99
Tissue fillers, intraorbital hyaluronic acid for enophthalmos *(Letter)*, 1101
Tonometry, rebound, influence of corneal properties on, 80
Toxoplasmosis, treated congenital, new eye lesions in, 553
Trabeculectomy
  anesthesia for phacotrabeculectomy *(Letter)*, 752
  comparison of 1-site and 2-site phacotrabeculectomy, 447, 1130
  filtering blebs and aqueous pathway, 1154
  longitudinal rates of postoperative adverse outcomes after glaucoma surgery, 1109
  needling revision of, 1148
  outcomes *(Letter)*, 1102
  phacoemulsification vs. combined phacotrabeculectomy in chronic angle closure glaucoma with cataract, 2167
  subconjunctival bevacizumab as adjunct to, 2141
  trab vs. tube, a 15-year retrospective *(Editorial)*, 1107
Transplantation
  CMV retinitis after hematopoietic stem cell transplantation with alemtuzumab, 1766
  corneal
    donor age and corneal endothelial cell loss after, 627
    donor age and outcome of, 620
    same-sizing vs. oversizing donor trephines in keratoconus, 268
  of limbal epithelial stem cells, 1989
  prospective study of pterygium extended removal followed by extended conjunctival transplantation, 1663
Trauma
  combat ocular trauma visual outcomes during Operations Iraqi and Enduring Freedom, 2235
  CT underestimation of soft tissue entrapment in pediatric orbital floor fractures, 1620
  perforating globe injuries during Operation Iraqi Freedom, 2087
  predicting vision survival after open globe injury, 202
  seatbelt use, airbag deployment, and ocular injuries, 573
  severe eye injuries in war in Iraq, 377
Traumatic graft dehiscence after PK, 276
Travoprost
  mechanism of action, 790
  meta-analysis of 24-hour IOP studies evaluating efficacy of glaucoma medications, 1117
Treatment adherence
  doctor–patient communication, health-related beliefs and adherence in glaucoma, 1320
  eye drop compliance in religious fasting *(Letter)*, 1440
Triamcinolone
  adjunctive triamcinolone acetonide in silicone-filled eyes for proliferative vitreoretinopathy, 1938
  intraocular concentration of triamcinolone acetonide after intravitreal injection (rabbit), 1372
  intravitreal, blood glucose and *(Letter)*, 916
  intravitreal *(Letter)*, 1436
  intravitreal triamcinolone acetonide vs. focal/grid photocoagulation for diabetic macular edema, 1447
  sub–Tenon's capsule, ptosis after *(Letter)*, 410
  tachyphylaxis to intravitreal anti-VEGF therapy in AMD, 2199
Tropicamide and myopia progression *(Letter)*, 1103
Trypsin digestion, in incontinentia pigmenti retinopathy, 893
Tulane University after Katrina *(Letter)*, 921
Tumors
  carcinosarcoma of orbit, 2065
  combined hamartoma of retina and RPE, 2246
  hemangioblastoma of optic nerve, 2094
  hemangioblastomas in von Hippel–Lindau disease
    retinal capillary, 181
      intravitreal ranibizumab for, 1957
    retrobulbar, 1382
  melanoma
    baseline echographic characteristics of tumors in Collaborative Ocular Melanoma Study, 1390
    conjunctival primary acquired melanosis and risks for progression to, 511
    latitude and *(Letter)*, 757
    modeling survival from choroidal melanoma with neural networks, 1598
    routes of extraocular extension of, 1778
    small choroidal *(Letter)*, 2319
    square procedure for periocular cutaneous melanoma, 2295
  Merkel cell carcinoma
    of eyelid, 195
    (Letter), 1643
  myxofibrosarcoma of orbit, 1237
  orbital lymphoproliferative, 1626
  pigmented squamous cell carcinoma in situ of conjunctiva, 1673
  retinoblastoma
    conservative treatments for, 1405
    diffuse infiltrating, clinical spectrum of, 2253
    intraarterial melphalan for, 1398
  topical interferon alfa-2b treatment
    of conjunctival and corneal intraepithelial neoplasia, 1291
    vs. surgical excision for primary ocular surface squamous neoplasia, 1297
Twin studies, of corneal hysteresis and ocular pulse amplitude, 1545

U

Ultrasound biomicroscopy
  in anterior uveitis *(Letter)*, 1851
  plateau iris in primary angle closure subjects, 430
Ultrasound pachymetry, and OCT measurements of central corneal thickness *(Letter)*, 2315
Utilities for 5 common diseases, impact of anchor point on, 898
Uveal melanoma
  baseline echographic characteristics of tumors in Collaborative Ocular Melanoma Study, 1390
  conjunctival primary acquired melanosis and risks for progression to, 511
  latitude and *(Letter)*, 757
  modeling survival from choroidal melanoma with neural networks, 1598
  routes of extraocular extension of, 1778
  small choroidal *(Letter)*, 2319
  square procedure for periocular cutaneous melanoma, 2295

Uveitis
anterior
in juvenile idiopathic arthritis, 1833
ultrasound biomicroscopy in *(Letter)*, 1851
antimetabolite drugs for noninfectious ocular inflammation, 1826
Behçet's disease in Chinese patients, 312
cataract surgery in *(Letter)*, 1431
human immunodeficiency virus–induced, 2062
mycophenolate mofetil after methotrexate for scleritis and, 1416
posterior, aqueous humor analysis for diagnosis of, 306

V

Value-based medicine *(Letter)*, 2099
Vascular endothelial growth factor (VEGF)
anti-VEGF pharmacotherapy for AMD *(Ophthalmic Technology Assessment)*, 1837
soluble VEGF receptor-1 in vitreous in proliferative diabetic retinopathy, 1916
tachyphylaxis to intravitreal anti-VEGF therapy in AMD, 2199
VEGF gene polymorphisms and AMD risk, 1899
vitreous levels of bevacizumab and VEGF-A in choroidal neovascularization, 1750
vitreous levels of SDF-1α and VEGF in ROP, 1065
Vasculature
body mass index and vein occlusion *(Letter)*, 917
central retinal vein occlusion
interventions for *(Letter)*, 219
radial optic neurotomy for, 174
glaucoma and peripheral vascular endothelial dysfunction, 1173
oxygen saturation, cerebral blood flow, and retinal vessel diameters, 887
retinal blood flow response to posture change in glaucoma, 246
retinal vasculature as a fractal, 1951
retinal vessel caliber and incidence of age-related cataract, 1693
3D OCT imaging of cystoid macular edema in retinal vein occlusion, 355
VEGF. *See* Vascular endothelial growth factor
Verteporfin treatment. *See* Photodynamic therapy
Vision impairment/loss
direct costs of blindness experienced by patients enrolled in managed care, 11
keratoprosthesis surgery for end-stage corneal blindness in Asian eyes, 503
low vision and blindness in rural Chinese adults, 1965
predicting vision survival after open globe injury, 202
rapid assessment of avoidable blindness in Kunming, China, 969
Singapore Malay Eye Study, vision impairment, ocular conditions, and vision-specific function, 1973
Vision rehabilitation and intraocular telescopes *(Letter)*, 1437
Visual acuity
Baltimore Pediatric Eye Disease Study
low concordance of fixation preference with visual acuity in preschool children, 1796
prevalence of decreased vision in preschool children, 1786
binocular vision after surgery to remove a unilateral epiretinal membrane, 1930
after cataract extraction in adult Latinos, 815
combat ocular trauma visual outcomes during Operations Iraqi and Enduring Freedom, 2235
low luminance function and geographic atrophy in AMD, 1480
in macular degeneration patients measured with Snellen and Early Treatment Diabetic Retinopathy Study charts, 319
mandating comprehensive eye examinations for children *(Editorial)*, 1271
more intense vs. standard early verteporfin treatment of neovascular AMD, 134
and mortality in Chinese population, 802
natural history and prognosis for neovascular AMD, 116 (erratum, 1524)
natural history of visual outcome in NAION, 298
OCT retinal parameters and visual acuity in neovascular AMD, 2206
one-year results of PDT in AMD and polypoidal choroidal vasculopathy in Japanese patients, 141
outcome measures *(Letter)*, 1267
results after second surgery for macular hole, 158
after scleral fixation of posterior chamber IOLs in children, 67
after subthreshold diode micropulse photocoagulation for central serous chorioretinopathy, 2229
after surgical removal of peripapillary choroidal neovascularization in presumed ocular histoplasmosis syndrome, 540
survival of central vision in end-stage glaucoma, 1162
three-year results of Artisan/Verisyse phakic IOL implantation, 464
Visual evoked potentials
Joubert syndrome, 2286
multifocal
patient opinions of clinical tests used in glaucoma management, 2127
visual function–optic nerve structure correlation, 440
Visual field defects
changes after transient IOP elevation, 667
effect of nilvadipine on visual field and ocular circulation in glaucoma, 2049
at follow-up in Ischemic Optic Neuropathy Decompression Trial, 1809
glaucoma and quality of life, 233
impact of visual field loss on quality of life in glaucoma, 941
IOP fluctuation and visual field progression, 1123
nonuniform pressure generation in bitemporal hemianopsia, 560
and optic nerve head topography in open-angle and angle-closure glaucoma, 239
survival of central vision in end-stage glaucoma, 1162
visual field progression criteria of 3 major glaucoma trials, 1557
Visual function
correlation with optic nerve structure, 440
15 years after optic neuritis, 1079
prognostic factors affecting visual outcome in *Acanthamoeba* keratitis, 1998
Singapore Malay Eye Study, vision impairment, ocular conditions, and vision-specific function, 1973
Vitamins. *See also* Antioxidants
supplements and age-related eye conditions, 1203
vitamin E and age-related cataract in randomized trial of women, 822
vitamin usage patterns in prevention of advanced AMD, 1032
Vitrectomy
contribution of vitreous cytology to final clinical diagnosis, 1944
diabetic
and lens status *(Letter)*, 415
vitreous cavity hemorrhage after, 525
incidence of endophthalmitis after 20- and 25-gauge vitrectomy, 2215
OCT and histopathology of sutureless vitrectomy wounds, 2221
vs. scleral buckling *(Letter)*, 1634
for symptomatic lamellar macular hole, 884
in X-linked retinoschisis, 718
(Letter), 920
Vitreous levels
of bevacizumab and VEGF-A in choroidal neovascularization, 1750
of reactive oxygen species in proliferative diabetic retinopathy, 734
of SDF-1α and VEGF in ROP, 1065
soluble VEGF receptor-1 in vitreous in proliferative diabetic retinopathy, 1916

von Graefe's sign, eyelid retraction, lid lag, and lagophthalmos in Graves' ophthalmopathy, 1083
von Hippel–Lindau disease
  retinal capillary hemangioblastomas in, 181
    intravitreal ranibizumab for, 1957
  retrobulbar hemangioblastomas in, 1382

W

Water drinking test in glaucoma patients, 1566
Wisconsin Epidemiologic Study of Diabetic Retinopathy
  25-year progression of retinopathy in type 1 diabetes, 1859 *(Editorial)*, 1857

X

X-linked retinoschisis
  (Letter), 920
  vitreous surgery in, 718

Z

Zinc, *CFH* and *LOC387715/ARMS2* genotypes and treatment with antioxidants and zinc for AMD, 1019